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ABSTRACT
Chronic Effects of Methylphenidate on Neuronal Viability and Plasticity
by
Hannah V. Oakes

Methylphenidate (MPH) is the most commonly prescribed drug to treat Attention Deficit
Hyperactivity Disorder (ADHD). ADHD is now considered a life-long disorder; therefore,
patients take MPH from adolescence into adulthood, highlighting the need for research studying
chronic MPH use. MPH increases dopamine and norepinephrine within the synaptic cleft;
therefore, chronic use of MPH may lead to changes within important dopaminergic pathways.
One pathway, the mesolimbic pathway, includes the hippocampus, an area where adult
neurogenesis occurs. We investigated the effects of chronic low and high doses of MPH on
neurogenesis and examined levels of a few key proteins linked to cell proliferation in the
hippocampus. Low dose MPH appears to increase cell proliferation and cell survival in the
hippocampus, and these effects are accompanied by increases in vascular endothelial growth
factor (VEGF), the receptor for brain-derived neurotrophic factor (TrkB), and beta-catenin.
While high dose MPH may initially increase neuronal proliferation, newly-generated neurons are
unable to survive long-term, and decreases in VEGF, TrkB, and beta-catenin are observed with
chronic high dose MPH.

Another major dopaminergic pathway is the nigrostriatal pathway, which is involved in motor
control and degenerates with Parkinson’s disease. Chronic use of MPH appears to sensitize
dopaminergic neurons within this pathway to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,62

tetrahydropyridine (MPTP), but the cause of this sensitization is unknown. The autooxidation of
excess dopamine forms dopamine-quinones that lead to free radical production, but the
antioxidant, glutathione, can protect neurons. However, we showed that chronic MPH increases
dopamine-quinone formation and causes a subsequent glutathione depletion within the striatum.
Therefore, oxidative stress may sensitize dopamine neurons to MPTP.

We also assessed the vulnerability of dopaminergic neurons in the nigrostriatal pathway to
MPTP after chronic MPH in females. Interestingly, proestrus (high estrogen) females were more
sensitive to MPTP than anestrus (low estrogen) females. Similar to males, chronic MPH caused a
depletion in glutathione that was further decreased following MPTP exposure. However, chronic
MPH did not significantly alter dopaminergic neuronal numbers or quinone formation in
females. These studies highlight some of the potential effects of chronic MPH use.
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CHAPTER 1. INTRODUCTION

Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder
characterized by inattention, hyperactivity, and impulsivity. Over the past few decades, there has
been a steady increase in the number of children diagnosed with ADHD. The Centers for Disease
Control and Prevention (CDC) reports that as of 2016, 6.1 million children have been diagnosed
with ADHD in the United States (Danielson et al. 2018). Additionally, in the past, ADHD was
thought of as a childhood disorder; however this perception of ADHD has changed, and ADHD
symptoms are known to persist from childhood to adulthood in 80% of individuals diagnosed as
children (Faraone 2018; Klein et al. 2019). Thus, many children continue to take medications for
ADHD well into adulthood (Bonvicini et al. 2016). Moreover, many individuals are
misdiagnosed with ADHD that do not meet the full diagnostic criteria medically, further
increasing the number of individuals diagnosed with and treated for ADHD.
ADHD is diagnosed using criteria found in the American Psychiatric Association’s
Diagnostic and Statistical Manual, fifth edition (DSM-5). The criteria rely heavily on selfreporting or reporting from parents. The DSM-5 lists two categories, inattention and
hyperactivity-impulsivity, and multiple symptoms that signify each category. Children up to the
age of sixteen must exhibit six or more symptoms that are inappropriate for their developmental
level in each category for at least six months. Individuals seventeen years or older must exhibit
five or more symptoms in each category. Individuals with inattention may exhibit the following
symptoms: fail to give close attention to details resulting in careless mistakes, have difficulty
holding their attention on task, fail to follow through with schoolwork, chores, or workplace
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tasks, have trouble organizing tasks, reluctant or avoid tasks that require mental effort over an
extended period of time, lose things that are needed to complete tasks often, and become easily
distracted. Hyperactivity may present as fidgeting, running, and climbing at inappropriate times
(often seen as restlessness in adults), unable to do activities quietly, always on the go, and
excessive talking. Impulsivity is characterized by blurting out answers before a question has been
completed, trouble waiting turns, and often interrupts or intrudes on others (Attentiondeficit/hyperactivity disorder (adhd) 2019; Health 2009; Tarver et al. 2014). Moreover,
symptoms must have been present before the age of twelve, present in two or more settings,
interfere with the quality of life, and not better explained by another mental disorder.
ADHD is further characterized by three different presentations: inattention,
hyperactivity/impulsivity, and a combined presentation. An individual is characterized as
inattentive when enough symptoms of inattention, but not hyperactivity-impulsivity were present
for the past six months. A hyperactivity-impulsivity presentation is characterized by a majority
of hyperactivity-impulsivity symptoms within the past six months. A combined presentation is
when enough symptoms from all criteria were present for the past six months (Attentiondeficit/hyperactivity disorder (adhd) 2019; Posner et al. 2020). At present, four developmental
trajectories are known, starting with early onset or preschool ADHD occurring at three to five
years of age, middle childhood six to fourteen years, middle childhood with adolescent offset,
and adolescent or adult onset from sixteen years and older (Posner et al. 2020). Altogether, the
DSM-5 provides a guideline for diagnosing ADHD that is more of a qualitative assessment than
a quantitative one.
The cause of ADHD is unknown, but there are many factors that may increase the risk for
ADHD. These risk factors include prenatal smoking, prematurity or low birth weight, and diet
13

(Posner et al. 2020; Tarver et al. 2014). Additionally, males are two times more likely to be
diagnosed with ADHD than females (Sridhar et al. 2017). Furthermore, ADHD has been linked
to abnormalities in several different neurotransmitter systems. For example, cognitive control
and symptom severity has been linked to glutaminergic deficits in frontal cortical and striatal
regions. Further, methylation of the serotonin transporter is linked to an increase in the severity
of symptoms (Faraone 2018). With so many different pathways with altered functions,
individuals with ADHD also have comorbidities such as anxiety, mood, substance use, sleep
disturbances, and personality disorders (Faraone 2018). Additionally, single photon emission
computed tomography (SPECT) revealed that there is decreased cerebral blood flow in the
temporal and cerebellar region and increased blood flow in the subcortical and thalamic regions
in the brains of individuals with ADHD (Gustafsson et al. 2000).
Differences in brain morphology may also contribute to ADHD. Individuals with ADHD
have decreased global brain volume. In particular, volume reductions have been observed in the
nucleus accumbens, amygdala, caudate, hippocampus, and putamen when compared to controls
(Faraone 2018). These reductions appear to involve both white and grey matter. Decreased white
matter is seen in areas such as the striatum, frontal, temporal, and parietal lobes, and decreased
grey matter is noted in areas that form the frontostriatal circuits (Faraone 2018; Nagel et al.
2011; Nakao et al. 2011; Posner et al. 2020; Tarver et al. 2014). There are many brain structures
that are altered in individuals with ADHD, but the prefrontal cortex, sensory cortex, motor
cortex, anterior cingulate cortex, parietal cortex, striatum, and thalamus are affected more than
other brain regions (Frolich et al. 2014). Naturally, research on the pathology of ADHD has
expanded to neural circuits involving the areas listed above. For example, individuals with
ADHD appear to have reduced activation of the mesolimbic neural circuit when anticipating
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rewarding outcomes. Alterations in the mesolimbic circuit are noteworthy, as, it is associated
with motivated behaviors, anticipated outcomes, and reinforced learning (Posner et al. 2020).
ADHD has a complex etiology, but evidence indicates that genetics appear to play a role,
as there are heritability estimates around 0.7% (Posner et al. 2020; Tarver et al. 2014; Tistarelli
et al. 2020). No single gene or genetic risk factor has been identified, suggesting that ADHD
may develop from the interactions of several different genes (Tarver et al. 2014; Tistarelli et al.
2020). Much of the research has focused on genes involved in dopaminergic and noradrenergic
transmission. Genes of interest include the dopamine transporter, norepinephrine transporter, and
dopamine receptors, D4 and D5 (Klein et al. 2019; Tarver et al. 2014). Increased levels of
dopamine transporter are seen in ADHD brains (Klein et al. 2019). Inattention presentation has
been associated with increased dopamine receptors (D2 and D3) and decreased synaptic
dopamine in the striatum and decreased DA synthesis in the nucleus accumbens (Volkow et al.
2012).
The treatment of ADHD includes behavioral modification and pharmacotherapy. Many
medical organizations such as the National Institutes of Health recommend the use of
medications to manage ADHD symptoms, along with behavioral modification. The medications
used to treat ADHD target dopamine and norepinephrine; if the drugs increase dopamine, they
are considered psychostimulants. There are some non-stimulant medications that are used to treat
ADHD, such as atomoxetine, but psychostimulants are generally favored due to well-established
efficacy (Gibson et al. 2006). Psychostimulants were first used in children in the 1930s and are
considered first-line treatment for management of ADHD symptoms today.
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Norepinephrine and Dopamine
Norepinephrine (NE) is sometimes referred to as noradrenaline; therefore, NE containing
neurons are referred to as noradrenergic neurons. Noradrenergic neurons in the locus coeruleus
project throughout the brain; however, the projection of noradrenergic neurons to the limbic
system is highly relevant to the current work. NE is thought to play a role in sleep and
wakefulness, attention, and feeding behavior (Martins et al. 2017). NE is released into the
synaptic cleft following an action potential, where it interacts with α- and β-adrenergic receptors
on both pre- and postsynaptic sites.
Dopamine (DA) is produced in four major pathways within the CNS, including the
mesocortical, mesolimbic, nigrostriatal, and tuberoinfundibular pathways. Two of these, the
nigrostriatal pathway, and the mesolimbic pathway, are highly relevant to the research in this
dissertation. The mesolimbic pathway originates in the ventral tegmental area and projects to the
amygdala, hippocampus, and the nucleus accumbens (Juarez Olguin et al. 2016). The
mesolimbic pathway is important in reward and motivation (Klein et al. 2019). The nigrostriatal
pathway is responsible for motor function, learning, and modulation of pain (Haber 2014).
Neurons originating in the substantia nigra project to the caudate and putamen nuclei of the
striatum, forming the nigrostriatal pathway. The nigrostriatal pathway plays an important role in
voluntary movement control by modulating corticostriatal transmission directly in neurons
expressing the DA receptor, D1 resulting in movement activation (Martins et al. 2017).
Altogether, DA is thought to play a major role in modulation of behavior and cognition, body
movement, motivation, reward and reinforcement, inhibition of prolactin production, nausea,
learning, sleeping, and dreaming (Haber 2014; Juarez Olguin et al. 2016; Klein et al. 2019).
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DA and NE are both catecholamines that are derived from tyrosine. Tyrosine hydroxylase
and the cosubstrate oxygen and cofactor tetrahydrobiopterin catalyze the reaction from the amino
acid tyrosine to dihydroxyphenylalanine also known as DOPA. The formation of DOPA is the
rate-limiting step in the reaction. DOPA is then catalyzed by DOPA decarboxylase to yield DA.
In noradrenergic neurons, the presence of the enzyme dopamine-β hydroxylase catalyzes the
conversion of DA to NE (Figure 1.1).
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Figure 1.1 Dopamine and Norepinephrine Synthesis. Tyrosine is converted to
dihydroxyphenylalanine (DOPA) by tyrosine hydroxylase. DOPA is then converted to dopamine
by DOPA decarboxylase. Finally, dopamine is converted to norepinephrine by the catalysis
dopamine-β hydroxylase.
18

Once DA or NE is synthesized within presynaptic neurons, these catecholamines are
moved into vesicles by vesicular monoamine transporter 2 (VMAT-2). Vesicles provide a stable
environment for catecholamines, because they can maintain a lower pH (Klein et al. 2019) . The
catecholamines are then released into the synaptic cleft upon vesicular fusion with the plasma
membrane, which occurs following an influx of Ca2+. Dopamine may be released at the axon
terminus following an action potential, but dopaminergic neurons may also release DA from
their cell bodies and dendrites (Liu and Kaeser 2019). DA signaling is terminated in the synaptic
cleft by the reuptake of DA through the dopamine transporter (DAT). DA can then be recycled
back into vesicles by VMAT-2 or broken down by the enzymes, monoamine oxidase (MOA) and
catechol O-methyltransferase (COMT). Similar to dopamine, NE is cleared from the synaptic
cleft by the norepinephrine transporter (NET). NE is then recycled or broken down by the same
enzymes that catabolize DA, MOA and COMT. Interestingly, DA can be taken back up into the
cell by the NET as well as the DAT (Klein et al. 2019; Volkow et al. 2012). In fact, DA has a
greater affinity for the NET than the DAT, implying that DA may be released by noradrenergic
neurons as well as dopaminergic neurons (Konova et al. 2013). Interestingly, noradrenergic
neurons located in the hippocampus are known to release DA (Klein et al. 2019).
DA released into the synaptic cleft can interact with presynaptic or postsynaptic DA
receptors. There is evidence that DA also binds to and activates adrenergic receptors (Klein et
al., 2019). There are two groups of DA receptors D1-like and D2-like. D1-like receptors include
D1 and D5, whereas D2-like receptors include D2, D3, and D4 (Xing et al. 2016). All DA
receptors are metabotropic and lead to the activation of second messengers (Klein et al. 2019).
D1 and D5 receptors are mainly found at post-synaptic sites, while D2 and D3 can be found both
pre- and post-synaptically. D4 is expressed in the retina (Klein et al. 2019). Moreover, D2-like
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receptors have a greater affinity for DA than the D1-like receptors. Thus, it is believed that D1like receptors are activated by high concentrations of DA (phasic release), and D2-like receptors
are activated by low concentrations of DA (tonic release) (Klein et al. 2019).
D1-like receptors are found in the caudate putamen of the striatum, nucleus accumbens,
substantia nigra pars reticulata, olfactory bulb, amygdala, and frontal cortex. D-2 like receptors
can be found in the striatum, core of the nucleus accumbens, ventral tegmental area,
hypothalamus, amygdala, cortical areas, hippocampus, and pituitary. D2 receptors are capable of
inhibiting DA synthesis, enhancing DA uptake, and regulating VMAT2 expression (Liu and
Kaeser 2019). When presynaptic D2 receptors are activated they inhibit neuron firing (Liu and
Kaeser 2019). D2 receptors that inhibit DA synthesis and inhibit neuron firing and thus, the
release of DA, are known as autoreceptors and they help to maintain homeostatic levels of DA
(Juarez Olguin et al. 2016). Since DA dysfunction is thought to be a major part of ADHD,
medications used to treat ADHD often target the DA system and may normalize DA function.
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Methylphenidate
In the United States alone, 3.5 million children receive medication to alleviate the
symptoms of ADHD (Sridhar et al. 2017). Clinical trials have shown that short-term treatment
with medication is effective, but little is known about the long-term effectiveness (Posner et al.
2020). Psychostimulants were first used to treat hyperactivity in the 1930s and continue to be
used today. Side-effects of psychostimulants include appetite suppression, dry mouth, and nausea
(Golmirzaei et al. 2016). Long-term use of stimulants affects growth trajectories due to appetite
suppression; therefore, drug holidays are suggested (Posner et al. 2020). Children often take the
medication throughout the weekdays and do not take the medication on weekends.

Figure 1.2 The molecular structure of methylphenidate

Methylphenidate (MPH, Figure 1.2), sold as Ritalin®, Concerta™, Metadate©, Methylin®,
and Daytrana©, is the most commonly prescribed psychostimulant for the treatment of ADHD.
Supporting this, several trials have shown MPH to be more effective than other ADHD
medications, such as atomoxetine (Hanwella et al. 2011). MPH is a psychostimulant that inhibits
21

dopamine (DA) and norepinephrine (NE) reuptake by blocking dopamine and norepinephrine
transporters (DAT and NET), thereby increasing the amount of these catecholamines in the
synaptic cleft (Figure 1.3). MPH is a racemic mixture composed of d-MPH and l-MPH, both
isomers increase extracellular DA and NE; however, the d-isomer is more potent.

Figure 1.3 Methylphenidate mechanism of action. MPH is a psychostimulant that inhibits
dopamine (DA) and norepinephrine (NE) reuptake, increasing the amount of these
catecholamines in the synapse. MPH inhibits the reuptake of DA and NE by blocking dopamine
or norepinephrine transporters (DAT and NET), respectively. However, MPH has a greater
affinity for DAT than NET.
22

Blockade of DAT by MPH is dose-dependent, and a clinically relevant, oral dose of 0.25
mg/kg or a plasma concentration of 5.7 ng/ml will occupy 50% of total DAT in the brain (Krause
et al. 2000). It is commonly thought that MPH has a greater affinity for the DAT than the NET.
However, in 2010 Hannestad and colleagues showed that 0.14 mg/kg of MPH is all that is
needed to occupy 50% of total NET in the brain (Hannestad et al. 2010). This is a lower dose
than is needed to occupy 50% of total DAT in the brain (0.25 mg/kg). This means that an
individual taking a MPH dose of 0.5 mg/kg would have about 80% of the total NET in the brain
occupied (Hannestad et al. 2010). The average effective MPH dose given to children is 0.7 to 0.9
mg/kg, and for adults, the average dose is 1.1 mg/kg (Hannestad et al. 2010). Moreover, the NET
has a greater affinity for DA than the DAT. It appears that DA is cleared by the NET and the
DAT in the synaptic cleft, and which one is used depends on which transporter is more abundant
and the brain-region of interest. Therefore, MPH binding and blocking both the NET and the
DAT may have the overall effect of increasing the amount of extracellular DA, leading to the
therapeutic effect of MPH (Hannestad et al. 2010). Additionally, the increase in DA in the
synaptic cleft due to MPH is known to upregulate the DAT in the ventral striatum, which could
lead to increases in the dose of MPH required to achieve the same therapeutic effect (Wang et al.
2013).
Under normal conditions, synaptic vesicles in dopaminergic neurons may contain
concentrations of DA as high as 1.0 M (Monzani et al. 2018). However, MPH is capable of
further increasing the amount of DA taken up into vesicles via regulation of VMAT-2 activity
(Fleckenstein and Hanson 2003). In fact, a single dose of MPH leads to an increase in the
amount of DA released following vesicular fusion. DA in the synaptic cleft may then interact
with D2 receptors. Activation of D2 receptors helps to redistribute vesicles from the membrane
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to the cytoplasm, where they begin reuptake of cytosolic DA via VMAT-2. Additionally, there is
a redistribution of VMAT-2 from membrane-associated vesicles to cytoplasmic vesicles further
increasing the reuptake of DA (Sandoval et al. 2002; Volz et al. 2008). Moreover, DA reuptake
into membrane-associated vesicles is also increased because VMAT2 activity is upregulated in
vesicles that remain associated to the membrane. Overall, more DA is taken up into vesicles
leading to an increase in DA release (Sandoval et al. 2002; Volz et al. 2008).
Extracellular DA levels can be homeostatically controlled via presynaptic autoreceptors
activation. Specifically, the activation of presynaptic D2 and D3 receptors decreases impulsetriggered vesicular DA release, leading to reduced signaling at postsynaptic D1 and D2 receptors
(Frolich et al. 2014). Autoreceptor activity leads to decreased background firing rates and
increased signal to noise ratio, which MPH has been shown to do in striatal cells (Volkow et al.
2001). In fact, both a D1 and D2 antagonist are both needed to block the effects of MPH (Riddle
et al. 2005).
Different responses to MPH may be due to an individual’s baseline dopaminergic tone,
DAT availability, and sex. A good clinical outcome is associated with a high baseline DA release
and high baseline of DAT (Krause et al. 2000; Volkow et al. 2002). One’s sex can also affect the
response to MPH. Women have lower plasma concentrations of MPH when compared to men
(Markowitz et al. 2003). This has also been shown in the case of rodents, where females have
higher brain concentrations of MPH than males (Bentley et al. 2015). There are sex differences
in DAT density and extracellular DA clearance, and an upregulation of male striatal D1 receptor
when compared to females (Cummins et al. 2014; Frolich et al. 2014). These differences in DAT
and D1 receptor may possibly be related to the sex differences that are seen with MPH use.
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MPH can cause changes in brain plasticity in addition to changes in dopaminergic tone.
As mentioned earlier individuals with ADHD have altered brain structure and cerebral blood
flow. Interestingly, MPH increases cerebral blood flow in the frontal lobes, caudate nuclei, and
thalamic areas (Frolich et al. 2014; Gustafsson et al. 2000). Additionally, MPH strengthens the
connectivity of corticolimbic connections (Konova et al. 2013). Use of MPH has been associated
with increased neuroinflammation and oxidative stress in the brain (Faraone 2018). Additionally,
several studies indicate that MPH use may be a risk factor for addiction (Ashok et al. 2017;
Castells et al. 2016; dela Pena et al. 2014).
Due to the stimulant properties of MPH, high school and college students often misuse
MPH (Bonvicini et al. 2016). MPH may be abused as a “cognitive enhancer”, an appetite
suppressant, or for the euphoria it can produce following intravenous (IV) use (Advokat and
Scheithauer 2013; Posner et al. 2020). In 2017, an estimated 12% of college students ages 18-25
years old reported using ADHD medication as a cognitive enhancer or study drug (Abelman
2017). Additionally, one study found that individuals were injecting MPH to get “high” (Frauger
et al. 2016). IV injections of MPH have a similar pharmacodynamic effect as cocaine, as it
allows for rapid MPH uptake into the brain and a surge in extracellular DA levels within the
nucleus accumbens (Baladi et al. 2014; Frolich et al. 2014; Volkow et al. 2002). In fact, MPH is
more potent at the DAT than cocaine (Calipari et al. 2015) However, oral doses of MPH produce
a slower rate of distribution to the brain than cocaine, which helps prevent the misuse of MPH
through an oral route (Konova et al. 2013; Volkow et al. 2002). Therefore, the proper
administration of MPH, both the route of administration and dose, are critical in preventing
abuse and addiction. However, given the rise in MPH use and misuse, studies to determine the
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long-term effects of MPH on the brain are necessary. Important dopaminergic pathways may be
affected by MPH, including the mesolimbic pathway, which innervates the hippocampus.

Neurogenesis
As mentioned earlier, brain structure is altered in individuals with ADHD. One of the
areas that is impacted is the hippocampus, where volume reductions are seen hippocampus in
individuals with ADHD (Faraone 2018). The hippocampus is one of the few places in the brain
where neurogenesis occurs throughout an individual’s life. Neurogenesis is the “birth of new
neurons” and it occurs during development and into adulthood in these neurogenic niches (Kuhn
et al. 2018). Adult neurogenesis occurs in the subgranular zone (SGZ) of the dentate gyrus (DG)
of the hippocampus and the subventricular zone (SVZ), below the lateral ventricles. New
neurons produced by the SVZ migrate to the olfactory bulb, where they act as interneurons. My
research focused on neurogenesis in the hippocampus, where newly generated neurons are
incorporated into the DG of the hippocampus as granular cells (Figure 1.2).
The hippocampus is responsible for memory, learning, and emotion, and is comprised of
different areas that perform different functions. Of note, neuronal cell bodies within the
hippocampus lie within the Cornu Ammonis fields (CA1, CA2, and CA3) and the DG. Neurons
within the DG project to CA2, an area known to play a role in social memory and contextual
discrimination (Fares et al. 2019). In adulthood, newly formed DG neurons also excite CA3
neurons, an area of the brain that is important for memory recovery (Fares et al. 2019). The rate
at which neurogenesis occurs in the SGZ of the DG may be affected by many factors; these
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include aging, stress, genetics, medications, and exercise. Additionally, neurogenesis can be
influenced through modulation of neurotransmitter systems, including DA and NE.
The mesolimbic pathway provides dopaminergic input to the hippocampus and thus may
influence neurogenesis in the SGZ. Immunohistochemical analysis has shown dopaminergic
afferent fibers extending into the hippocampus, and that the D2 receptor is expressed in the DG
(Veena et al. 2011). Additionally, lesions of the dopaminergic afferent fibers to the hippocampus
or blockade of the D2 receptor decreases neurogenesis and impairs memory, while; activating D2
receptors increases neurogenesis and stabilizes memory (Aimone et al. 2014; McNamara et al.
2014; Veena et al. 2011).
Noradrenergic neurons originate from the locus coeruleus and project to many different
parts of the brain. Importantly, they also project to the limbic system, including the
hippocampus. Like DA, NE also appears to play an important role in neurogenesis, as lesions to
noradrenergic fibers projecting to the hippocampus decrease neurogenesis rate (Aimone et al.
2014). In addition, several classes of drugs that increase NE have been shown to increase
neurogenesis rates, including the serotonin-norepinephrine reuptake inhibitors (SNRIs). SNRIs
block the NET and serotonin transporter (SERT). These medications are used to treat mood
disorders such as depression and anxiety, and the increase in hippocampal neurogenesis that
SNRIs produce is believed to contribute to their efficacy (Lee et al. 2012). Given the fact that
both NE and DA appear to play a role in neurogenesis, it is possible that the NET and DAT
inhibitor, MPH, may influence neurogenesis.
Interestingly though, not all monoamine transport inhibitors have been shown to increase
neurogenesis. Results of experiments examining cocaine’s effect have been mixed, cocaine is a
psychostimulant that blocks the DAT, NET, and SERT. Studies with cocaine have shown that it
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can either increase or decrease the rate of neurogenesis (Castilla-Ortega et al. 2016; GarciaFuster et al. 2010; Lloyd et al. 2010; Sudai et al. 2011). For example, chronic subcutaneous
injections of cocaine (2 x 10 mg/kg/day) increased the rate of neurogenesis in the hippocampus
of mice (Lloyd et al. 2010). In contrast, impaired neurogenesis and decreased cell proliferation
was seen in rats that self-administered cocaine (1.5 mg/kg intravenous infusions) for 14 days
(Sudai et al. 2011). These discrepancies may be due to varied doses and animal models that are
used for these experiments. MPH has a similar mechanism of action to cocaine and may also
affect hippocampal neurogenesis. Therefore, we explore the effect that MPH has on neurogenesis
in this work.
A few studies have looked at the effects of MPH on neurogenesis, but these have yielded
contradicting results. An increase in neurogenesis was observed in adolescent rats treated orally
with MPH at low (5 mg/kg) or high (10 mg/kg) doses for 28 days (van der Marel et al. 2015).
Yet in another study, low oral doses of MPH (2.5 mg/kg or 5 mg/kg) for 21 days had no effect on
neurogenesis in adolescent mice, but a high dose (10 mg/kg) appeared to increase neurogenesis
when compared to controls (Lee et al. 2012). In agreement, another study found no effect on
neurogenesis when gerbils received 5 mg/kg MPH orally for 30 days (Schaefers et al. 2009).
Still, other studies have shown that intraperitoneal injections of a low (2 mg/kg) dose of MPH for
15 days given to adolescent rats resulted in no effect on the rate of neurogenesis, but did affect
the survival of newly generated neurons (Lagace et al. 2006). These conflicting results may be
due to differences in the length of treatment, doses of MPH, drug delivery, and the animal
model; moreover, these studies highlight the need for further investigation. In this dissertation a
dose of 1 mg/kg MPH given intraperitoneal (i.p.) twice daily was utilized as this dose and
method of delivery has been shown to be equivalent to a therapeutic oral dose given for the
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clinical treatment of ADHD (Gerasimov et al. 2000; Koda et al. 2010). The dose of 10 mg/kg
MPH i.p. was also used as this dose is equivalent to a therapeutic dose given for the treatment of
narcolepsy and representative of the recreational misuse of MPH (Valvassori et al. 2007).

Figure 1.4 Neurogenesis in the dentate gyrus. Adult neurogenesis occurs in the subgranular zone
(SGZ) of the dentate gyrus of the hippocampus.
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Proteins Related to Neurogenesis in the Hippocampus
The exact mechanism of how DA and NE affect neurogenesis is unknown. However, it
has been proposed that these neurotransmitters lead to differences in expression of several
proteins that may modulate neuronal development, growth, and survival. Several studies have
indicated that monoamines alter the expression of beta-catenin and vascular endothelial growth
factor (VEGF). In fact, other NET inhibitors, such as desipramine have been found to increase
expression of beta-catenin and VEGF (Rolando and Taylor 2014; Warner-Schmidt and Duman
2007; Zhao et al. 2008). Beta-catenin is a downstream effector of the Wingless-Int (Wnt)
pathway. Wnt proteins are glycoproteins that are known to affect cell proliferation and
differentiation, and beta-catenin is a key player involved in this signaling cascade (Hayat 2006).
Beta-catenin can be found associated with the cell membrane or in the cytoplasm near the
nucleus (Hayat 2006). Under normal conditions, beta-catenin levels are kept low, as it is
constantly phosphorylated and degraded, preventing the protein from traveling to the nucleus and
activating gene transcription. However, with the activation of the signaling cascade from Wnt,
beta-catenin is stabilized and can travel to the nucleus (Baines and Renaud 2017). Beta-catenin
then interacts with transcription factors that regulate genes associated with cell survival and
proliferation. In fact, increased beta-catenin levels can cause the transformation of normal cells
into malignant cells, and overexpression of beta-catenin has been reported in many cancers
(Averett et al. 2014).
Beta-catenin is important for normal hippocampal development (Rolando and Taylor
2014) by promoting proliferation of neuronal progenitor cells (Warner-Schmidt and Duman
2006; Yu et al. 2014). There is a decrease in neurogenesis when beta-catenin expression is
inhibited (Hui et al. 2014; Mostany et al. 2008; Rolando and Taylor 2014). Moreover, when the
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Wnt pathway is activated by antidepressants that block the reuptake of NE, quiescent neuronal
progenitor cells begin to proliferate (Rolando and Taylor 2014). As further evidence of betacatenin’s complex role in neurogenesis, beta-catenin is able to promote the synthesis of two other
proteins involved in neurogenesis, VEGF and brain-derived neurotrophic factor (BDNF) (Hui et
al. 2014; Tayyab et al. 2018).
VEGF has been shown to act as a neurotrophic factor in addition to promoting
angiogenesis. VEGF contributes to the neurogenic niche needed to promote the survival of newly
formed neurons. Neuronal progenitor cells, neurons, glial cells, and endothelial cells in the
hippocampus all express VEGF and its receptors; however, VEGF appears to affect neural
precursors separately from the effects it has on endothelial cells (During and Cao 2006). A direct
infusion of VEGF into the hippocampus results in increased neurogenesis (Warner-Schmidt and
Duman 2007; Zhao et al. 2008). Moreover, antidepressants that increase neurogenesis are known
to increase VEGF in the hippocampus, and blocking VEGF signaling inhibits the neurogenic
effect of antidepressants (Cao et al. 2004; Zhao et al. 2008). Exercise and an enriched
environment are known to increase neurogenesis within the hippocampus and VEGF appears to
play an important role in mediating this. VEGF is needed for exercise-induced neurogenesis
(Bettio et al. 2019) and VEGF knockdown inhibits neurogenesis in the hippocampus that is
produced when animals are subjected to an enriched environment (During and Cao 2006).
Additionally, overexpression of VEGF in rats was able to enhance hippocampal spatial memory
formation (Tillo et al. 2012).
BDNF is a neurotrophic factor that is responsible for neuronal growth and survival.
Upregulation of BDNF increases cell proliferation in neuronal cultures, and beta-catenin helps to
promote the synthesis of BDNF through the Wnt pathway (Tayyab et al. 2018). High
31

concentrations of BDNF are found in the hippocampus (Erickson et al. 2012), and infusion of
BDNF into the hippocampus of rats increases neurogenesis within the DG (Scharfman et al.
2005). Interestingly, neurogenesis can be induced in rodents even when BDNF is administered
peripherally (Erickson et al. 2012). The increased hippocampal neurogenesis produced by SSRIs
and SNRIs is associated with increases in BDNF in the hippocampus of rodent models of
depression and human patients treated by antidepressants (Jiang et al. 2014; Sairanen et al. 2005;
Tayyab et al. 2018).
Furthermore, BDNF’s receptor, tropomyosin receptor kinase B (TrkB) is expressed on
neural progenitor cells in the DG and is required for hippocampal neurogenesis, as deletion of
TrkB from neuronal progenitor cells hinders neurogenesis (Li et al. 2008). Activation of TrkB by
BDNF is known to promote cell growth and survival in serotonergic neurons (Erickson et al.
2012). Additionally, chronic treatment with antidepressants, which increases neurogenesis, also
leads to an upregulation TrkB mRNA in the hippocampus (Sairanen et al. 2005). Some studies
have shown that MPH may alter expression of BDNF and/or tropomyosin receptor kinase B
(TrkB) in the hippocampus and prefrontal cortex (Fumagalli et al. 2010); however, they have
yielded conflicting results. Some studies have found an increase in BDNF expression while
others have found a decrease in BDNF expression after MPH exposure (Fumagalli et al. 2010;
Lagace et al. 2006; Lee et al. 2012). As above, these differences may be due to the dose of MPH
used or the area of the brain studied. For example, one lab has shown an increase in BDNF in the
subgranular zone of the hippocampus with a high dose of MPH (10 mg/kg) (Lee et al. 2012),
while another has shown a decrease in BDNF in the hippocampus after exposure to a low dose of
MPH (2 mg/kg) (Lagace et al. 2006). Moreover, another lab found an increase in BDNF in the
striatum of animals exposed to a low dose of MPH (1 mg/kg) (Fumagalli et al. 2010).
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Additionally, age may also play an important role. One study showed that BDNF mRNA
decreased when juvenile rats were exposed to MPH but increased when adult rats were exposed
to MPH (Banerjee et al. 2009). This is interesting because natural aging has been associated with
a decrease in neurogenesis. As age increases BDNF levels remain unchanged, while TrkB
expression decreases (Aimone et al. 2014). Of note, MPH has been shown to either increase or
decrease TrkB, again depending on the area of brain studied. One study found that exposure to
MPH resulted in a decrease in BDNF and TrkB in the prefrontal cortex and an increase in BDNF
with no change in TrkB in the striatum (Fumagalli et al. 2010).
Another neurotrophic factor that is important for cell growth and survival is glial cell
line-derived neurotrophic factor (GDNF). GDNF and its receptor GDNF family receptor alpha 1
(GFRa1) are both expressed on adult-born granule cells in the hippocampus (Bonafina et al.
2019). Moreover, GDNF is decreased in the hippocampus of stressed or depressed rodents, and
antidepressants increase the mRNA of GDNF in rat astrocytes (Kajitani et al. 2012; Popova et al.
2017). Furthermore, exercise is known to increase neurogenesis, and voluntary running triggers
an increase in GDNF expression (Bonafina et al. 2019). Additionally, in vivo infusion of GDNF
into the hippocampus of rats results in increased neurogenesis (Chen et al. 2005). Additionally,
GDNF has been shown to support the survival of DA neurons (Allen et al. 2013). While a few
studies have looked at the effects MPH on BDNF, no studies have examined the effects of MPH
on GDNF.
Altogether, these results highlight the need to further investigate the effect of MPH on
neurogenesis. In chapter 2 of this dissertation, we look at how chronic MPH treatment affects the
proliferation and survival of granule cells within the DG of the hippocampus. Additionally, we
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examine the mechanism for this interaction by measuring the expression of these proteins related
to neurogenesis, beta-catenin, VEGF, BDNF, TrkB, or GDNF, are altered.

Dopamine-induced Oxidative Stress
Another important dopaminergic pathway is the nigrostriatal pathway, where neurons
project from the substantia nigra to the caudate and putamen nuclei of the striatum.
Approximately 80% of the DA in the brain is contained within the nigrostriatal pathway (Golan
D 2011; Stahl 2008). This pathway is primarily responsible for purposeful movement and
damage to this pathway can result in tremors, spasms, tardive dyskinesia, and Parkinson’s
disease. Unfortunately, it appears that DA may be capable of causing such damage.
Excess DA not stored in vesicles can contribute to oxidative stress. Oxidative stress
occurs when reactive oxygen species (ROS) overwhelm the body’s natural antioxidants. These
ROS include the, superoxide anion (O.−
2 ), hydrogen peroxide (H2O2), and hydroxyl radical (.OH).
Certain ROS known as free-radicals are unstable due to an unpaired electron. Depending on the
free-radical, it will readily donate or accept electrons to become stable. However, by donating or
accepting an electron, the free-radical sets off a chain reaction, further increasing the number of
free-radicals that are then able to interact with yet more, molecules (Betteridge 2000). Oxidative
stress becomes a problem, because free-radicals interact with macromolecules causing lipid
peroxidation, protein damage, cross-linking and fragmentation of proteins, and even DNA
double strand breaks (Betteridge 2000; Salim 2017). In addition, oxidative stress in the brain
increases the blood-brain barrier permeability, changing brain morphology, increasing
neuroinflammation, and can cause neurodegeneration (Salim 2017). As mentioned earlier, ROS
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also includes H2O2 as well as free-radicals. H2O2 can easily pass through cell membranes, and
when it comes into contact with transition metal ions, H2O2 produces hydroxyl radicals
(Betteridge 2000). Furthermore, the brain is enriched with transition metals such as iron (Fe) and
copper (Cu). In fact, chelated Fe and Cu levels can reach into the mM range; this is due to the
brains ability to use transition metals to increase the rate of a biochemical reaction (Cobley et al.
2018). Fe is also capable of assisting in many other neuronal functions including synthesis of the
myelin sheath (Todorich et al. 2009). Due to the importance of Fe, unsurprisingly, neurons
contain a reserve of chelated Fe that can be used when needed.
Indeed, the brain is particularly susceptible to oxidative stress. Another source of ROS
are the mitochondria. Mitochondria are cell organelles responsible for converting glucose to a
useful form of energy, adenosine triphosphate (ATP) using the electron transport chain and O2 in
a process known as oxidative phosphorylation. The brain consumes 20% of the total basal
oxygen due to the ATP needed for neurons to maintain ionic gradients and release
neurotransmitters as needed in addition to other cellular functions (Cobley et al. 2018).
Mitochondria have other functions in addition to the production of ATP. One function is the
breakdown of DA by enzymes located in the mitochondria (Figure 1.5). These enzymes are
known as monoamine oxidase A (MOA-A) and monoamine oxidase B (MOA-B). However, DA
is preferentially broken down by MOA-B, which is located on the outer space of the
mitochondrial inner membrane where few antioxidants exist (Cobley et al. 2018). Unfortunately,
when DA is broken down, H2O2 is produced as a byproduct (Stokes et al. 2000). The capacity of
MOA-A and MOA-B to generate H2O2 depends on the concentration of oxygen. When they are
saturated with oxygen, they produce a considerable amount of H2O2 (Cobley et al. 2018). Then,
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transition metal ions (especially Fe) are capable of converting H2O2 to .OH, further increasing
oxidative stress. In certain conditions, DA itself can also lead to oxidative stress.

Figure 1.5 The breakdown of Dopamine by monoamine oxidase. Dopamine can be metabolized
by the enzyme monoamine oxidase (MAO) within the mitochondria. MAO produces H2O2 when
it catalyzes dopamine to 3,4-dihydroxyphenylacetaldehyde. H2O2 may interact with Fe or Cu
producing a hydroxyl radical.
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DA is capable of autoxidizing at a physiological pH by dissociation of a hydroxyl group
creating a DA o-quinone which then forms an aminochrome and eventually forms H2O2 and
hydroxyl radicals (Figure 1.6). Under normal conditions, excess DA is sequestered in vesicles
with a lower pH to prevent DA autoxidation and contact with catalytic factors (Klein et al. 2019).
However, DA is capable of leaking out of synaptic vesicles and collecting in the cytosol (Zhang
et al. 2019). This means that free DA may be autoxidized without a catalysis and produce ROS.
However, Fe and Cu, as well as enzymes with peroxidase activity are capable of catalyzing DA
into DA o-quinone, speeding up the reaction and increasing the levels of DA o-quinones. The
capability of Fe and Cu to catalyze DA into harmful ROS and the stores of these transition
metals in neurons highlight the susceptibility that dopaminergic pathways have to oxidative
stress. For example, the nigrostriatal DA neuronal pathway accumulates ferrous ions that
promote DA oxidation (Klein et al. 2019). Quinones and other ROS generated from the
formation of quinones interrupt normal cell function by inducing oxidative stress throughout the
cell and indiscriminately damaging proteins, lipids, DNA, and other important macromolecules
which could potentially trigger apoptosis (Park et al. 2007).
DA o-quinones disrupt normal cell function by targeting cysteine residues on proteins. If
cysteine is not available, these quinones may target histidine and lysine residues as well
(Monzani et al. 2018). DA o-quinones reacting and forming adducts with cysteine residues is
particularly alarming, because cysteine residues are often found in the active site of enzymes.
This could be detrimental to the cell if enough enzymes are unable to participate in essential
reactions. Some proteins that DA o-quinones are known to form adducts with are crucial to
dopaminergic neurotransmission, including the DAT and tyrosine hydroxylase, the enzyme
responsible for DA synthesis. Of note, adducts can also be formed with parkin, a protein known
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to be altered in familial forms of Parkinson’s disease. Finally, DA o-quinones will also form
adducts and alter the functioning of proteins that have pivotal roles in maintaining ROS levels
such as, glutathione peroxidase, superoxide dismutase, and mitochondrial complexes in the
electron transport chain (Zhang et al. 2019; Zucca et al. 2017).
Oxidative phosphorylation occurs in mitochondria and is the process of using oxygen to
synthesize ATP. This is accomplished by the electron transport chain. The electron transport
chain consists of 4 protein complexes known as complex I, complex II, complex III, and
complex IV. Cells use NADH to carry electrons to complex I where they enter the electron
transport chain. Electrons usually flow through complexes I, III, and IV to release energy in a
step-wise fashion, leading to the production of ATP. Complex I is also known as
NADH:ubiquinone oxidoreductase is responsible for catalyzing the first step in the electron
transport chain by oxidizing NADH and transferring that energy to ubiquinone forming
ubiquinol. Ubiquinol carries two electrons to complex III. Complex III is also known as
ubiquinone-cytochrome c oxidase. Complex III uses the energy gained from the electrons to
oxidize semiquinone and reduce cytochrome c, pumping protons from the mitochondrial matrix
to the inner membrane space. If there is a decrease in electron transfer, oxygen can accept
electrons from complex III, resulting in superoxide formation (Dias et al. 2013). In fact, complex
I and III are both known to produce superoxide anions under normal physiological conditions
(Murphy 2009). Mitochondria have the enzyme superoxide dismutase and others to combat the
harmful ROS it produces. Unfortunately, these enzymes are the target of DA o-quinones.
When adducts are formed between DA o-quinones and enzymes, the enzymes are unable
to bind and remove ROS. Therefore, the ROS produced by the mitochondria are free to cause
mitochondrial damage, eventually leading to apoptosis. Furthermore, quinones are known to
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interrupt the normal functioning of mitochondria, further increasing the formation of radicals
(Segura-Aguilar et al. 2014). In response to DA quinones, isolated mitochondria exhibit
significant decreases in the activity of all 4 complexes (Jana et al. 2011). In fact, DA o-quinone
has been shown to form adducts with proteins in complexes I, III, and IV, greatly reducing their
function and producing free radicals (Zucca et al. 2017). Others have shown mitochondrial
membrane depolarization and even toxic effects via interactions with the electron carrier, NADH
(Bisaglia et al. 2010; Jana et al. 2011). Moreover, derivatives of DA quinones are also capable of
damaging mitochondria and contributing to oxidative stress.
DA o-quinone cycles to aminochrome and leukoaminochrome. Both conjugates are
unstable; however, aminochrome is more stable than leukoaminochrome. Aminochrome is
known to form adducts with and inhibit complex I in vitro in SHSY5Y cells that have been
differentiated into dopaminergic cells (Aguirre et al. 2012). Additionally, mitochondrial
dysfunction is seen when aminochrome is directly injected into the striatum (Zhang et al. 2019).
In addition, aminochrome accepts electrons from NADH to form leukoaminochrome-osemiquinone radical (Figure 1.6) which is a free-radical that is highly reactive with oxygen.
Leukoaminochrome-o-semiquinone will autoxidize back to aminochrome, while reducing
oxygen to create more ROS. Moreover, aminochrome continues to cycle to leukoaminochromeo-semiquinone and back causing the depletion of NADH (Zhang et al. 2019; Zucca et al. 2017).
NADH is an important electron carrier needed in the electron transport chain and without
NADH, ATP production is greatly reduced. Taken together, it is clear that aminochrome and
leukoaminochrome can be detrimental to mitochondrial function, and without ATP production
from mitochondria neurons may become apoptotic. Perhaps more significant is that
aminochrome is able to promote the formation of α-synuclein.
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The protein, α-synuclein has been implicated in neurodegenerative diseases including
Alzheimer’s and Parkinson’s disease (Segura-Aguilar et al. 2014). Normally, α-synuclein can be
found at the synapse within active and reserved synaptic vesicles in dopaminergic neurons,
where it plays a role in DA release. The importance of α-synuclein in regulation of DA release is
evidence that knock-out mice have decreased DA release within the striatum (Villar-Piqué et al.
2016). However, overexpression of α-synuclein can induce neurodegeneration in dopaminergic
neurons (Asanuma et al. 2003). When α-synuclein is overexpressed or mutated, it can begin to
aggregate, elongate, and assemble into an enriched β-sheet structure (Villar-Piqué et al. 2016).
These insoluble aggregates can form in the cell body or processes of neurons and are known as
Lewy bodies or Lewy neurites, respectively (Kalia and Lang 2015). Aggregated α-synuclein can
form toxic protofibrils known to destroy synaptic vesicular membranes, inhibit movement of the
cell cytoskeleton and accumulate in mitochondria where they inhibit complex I (Asanuma et al.
2003; Villar-Piqué et al. 2016). The damage to vesicular membranes and mitochondria can lead
to an increase in ROS. To guard against this, fibrils can be formed from α-synuclein protofibrils
to help prevent this damage.
Fibrils are larger and more stable than protofibrils and prevent the smaller protofibrils
from diffusing into surrounding cells where they can cause additional damage to surrounding
cells (Siddiqi et al. 2019). However, aminochrome as well as DA quinones will bind to αsynuclein and protofibrils, stabilizing them and preventing the formation of fibrils (Asanuma et
al. 2003; Miyazaki and Asanuma 2008; Monzani et al. 2018; Zucca et al. 2017). In addition,
increased ROS promotte the aggregation of α-synuclein in dopaminergic neurons, contributing
further to this vicious cycle (Salim 2017). This may be one mechanism by which dopaminergic
neurons are lost in Parkinson’s disease. Increased DA induces α-synuclein aggregation and the
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degeneration of neurons in the nigrostriatal pathway (Monzani et al. 2018). In fact, DA has long
been known to have a role in the degeneration of DA terminals (LaVoie and Hastings 1999). To
help prevent degeneration, dopaminergic neurons have evolved mechanisms to prevent oxidative
stress.

Neuromelanin
One such mechanism is the formation of neuromelanin. Free DA and metal ions can be
incorporated into neuromelanin to prevent oxidation. Neuromelanin is a polymer that makes up
the dark pigment found within the substantia nigra, where it is formed as a neuroprotective action
against DA oxidation. Once DA o-quinone forms aminochrome, it can be rearranged to 5,6
dihydroxyindole, then oxidized to 5,6 indolequinone which is polymerized to form neuromelanin
(Zhang et al. 2019). Neuromelanin can also be formed when DA o-quinone interacts with
cysteine forming cysteinyl-DA (Zucca et al. 2017). Neuromelanin also functions as an
antioxidant by scavenging ROS and binding and inactivating transition metals (Zhang et al.
2019). This chelation of metal ions prevents them from interacting with and oxidizing free DA.
Once neuromelanin is formed, it is sequestered in vesicles where it is stored. Additionally, the
number of vesicles and concentration of neuromelanin within them increase as we age and are
generally considered neuroprotective.
However, when dopaminergic neurons degenerate, as with Parkinson’s disease,
neuromelanin is released from the neuron into the extracellular space. Neuromelanin can then act
as a chemotaxin for microglia, leading to an immune response (Zucca et al. 2014; Zucca et al.
2017). Microglia phagosize neuromelanin and release pro-inflammatory factors such as tumor

41

necrosis factor α (TNFα), interleukin 6, nitric oxide, superoxide, and hydrogen peroxide (Cobley
et al. 2018; Zucca et al. 2014). Indeed, inflammation in the substantia nigra is part of the
pathology of Parkinson’s disease. Given these points, it is clear to see how neuromelanin can be
neuroprotective under normal physiological conditions but can also become neurotoxic.

Glutathione
Under normal physiological conditions, small amounts of DA o-quinone are made, and
the cell prevents any damage before it is done. In addition to incorporating DA o-quinone
derivatives into neuromelanin, the brain utilizes the antioxidant glutathione (GSH) to protect
neurons from the toxicity of quinones (Motaghinejad et al. 2016). In fact, GSH has been shown
to prevent DA-induced cell death in some rodent models (Park et al. 2007; Stokes et al. 2000;
Zhou and Lim 2009). GSH forms conjugation reactions with quinones or aminochromes
eventually leading to the formation of 5-S-cysteinyl DA or 4-S-glutathionyl-5,6dihydroxyindoline, respectively. 5-S-cysteinyl DA and 4-S-glutathionyl-5,6-dihydroxyindoline
may then be incorporated into neuromelanin (Zhou and Lim 2009) and some 5-S-cysteinyl DA is
released into cerebral spinal fluid. After the conjugation reactions, GSH becomes glutathione
disulfide (GSSG). Following the catalysis by GSH reductase and the input of energy in the form
of NADH, GSSG may be converted back into its reduced form GSH, so it can participate in
another conjugation reaction. Unfortunately, aminochrome is also competing for NADH to form
leukoaminochrome o-semiquinone radical and hydroxyl radicals (Figure 1.3) (Dagnino-Subiabre
et al. 2000; Munoz et al. 2012). The consequences of this are two-fold, excess quinone
production will deplete GSH as well as deplete the cofactor (NADH) needed to convert GSH
back to its reduced form. Thus, the depletion of GSH leads to the production of more free
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quinones, and therefore more radicals, leading to oxidative stress and eventually neurotoxicity
via apoptosis (Stokes et al. 2000). This becomes a vicious cycle when oxidative stress leads to
degradation of neuromelanin and the release of additional DA and metal ions, further increasing
the potential for oxidative stress (Meiser et al. 2013). Moreover, GSH levels are lower in neurons
when compared to other cells (Cobley et al. 2018), and glutathione activity is reduced as we age
(Juarez Olguin et al. 2016). Taken together it becomes apparent that the brain is particularly
susceptible to DA-induced oxidative stress. Therefore drugs, such as psychostimulants, that
increase synaptic DA levels may have detrimental effects on the dopaminergic pathways within
the brain.
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Figure 1.6 Dopamine and Oxidative Stress. DA can be oxidized to DA o-quinone at a
physiological pH. DA o-quinone then forms an aminochrome and with the aid of oxygen and
NADH generates radicals. Glutathione (GSH) conjugates to the dopamine o-quinone, which then
degrades to form 5-S-cysteinyl dopamine. 5-S-cysteinyl dopamine may be then incorporated into
neuromelanin or dumped into the cerebral spinal fluid. GSH can also conjugate to aminochrome
and become incorporated into neuromelanin. Neurotoxicity results when radicals are formed and
is further exacerbated when GSH is depleted.
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Oxidative Stress and Psychostimulants
Given the fact that psychostimulants increase levels of free DA in the synaptic cleft,
some studies have examined whether psychostimulants could contribute to oxidative stress.
Cocaine is a psychostimulant that has a similar mechanism of action to MPH, inhibiting the
reuptake of DA and NE, but also serotonin. Cocaine has been shown to increase H2O2 production
and lipid peroxidation in the striatum (Korpi et al. 2015; Lipaus et al. 2019; Pomierny-Chamioło
et al. 2013; Sharma et al. 2009; Vitcheva et al. 2015). Furthermore, treatment with antioxidants
lessened the oxidative stress (Korpi et al. 2015). Unfortunately, the antioxidant GSH appears to
be depleted in the striatum of rodent brains exposed to cocaine (Hirsch et al. 2018; PomiernyChamioło et al. 2013; Vitcheva et al. 2015). Additionally, exposure to cocaine can increase the
expression of proinflammatory cytokines such as TNFα and IL-1β in the nigrostriatal pathway
(Sajja et al. 2016). Interestingly though, many studies have indicated that cocaine alone does not
cause blatant neurotoxicity. For example, high doses of cocaine resulted in no significant
degeneration of axons in the striatum (Korpi et al. 2015). Moreover, rats treated with cocaine
exhibited no dopaminergic cell loss in the nigrostriatal pathway (Little et al. 2009).
The amphetamine psychostimulants have also been examined for their potential to induce
oxidative stress and neurotoxicity. These include methamphetamine, a popular drug of abuse,
and amphetamine, another commonly prescribed drug for ADHD. Amphetamines are substrates
for the monoamine transporters, competing with endogenous neurotransmitters for transportermediated uptake into the presynaptic neurons (Fleckenstein et al. 2007; Sitte et al. 1998). Once
the amphetamines are transported into presynaptic neurons, they promote the release of DA, NE,
and/or serotonin back into the synaptic cleft via reversal of monoamine transporter flux (Jones et
al. 1999; Rothman and Baumann 2003) In addition, amphetamines are capable of inhibiting
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MAO causing increases in the overall concentration of the monoamine transmitters (Korpi et al.
2015). Neurotoxicity can occur following amphetamine exposure and appears to result from a
combination of hyperthermia, excitotoxicity, mitochondrial dysfunction, and oxidative stress
(Seger 2010). Oxidative stress following amphetamine exposure likely occurs because of the
large increases in both intracellular and extracellular DA. As mentioned earlier, excess DA is
susceptible to autoxidation or catalytic oxidation to form toxic quinones. Multiple animal studies
have revealed the significant DA neurotoxicity that can be induced by methamphetamine and the
contributing role of DA quinones in this toxicity (Baldwin et al. 1993; Guillot et al. 2008; Kita et
al. 2003; LaVoie and Hastings 1999). Moreover, DA cell loss and GSH depletion in the
nigrostriatal pathway was also observed in postmortem brain tissue of chronic methamphetamine
users (Tong et al. 2018). Increases in intracellular DA appear to be more detrimental for the cell
than increases in extracellular DA. In support of this, blockade of DAT or inhibition of DA
synthesis after methamphetamine exposure reduces the toxicity associated with
methamphetamine (Kita et al. 2009; Korpi et al. 2015). The loss of dopaminergic neurons is
evident in experiments with chronic amphetamine use as well. Amphetamine exposure can
induce a significant loss in dopaminergic neurons that is accompanied by a decrease in DA,
DAT, and tyrosine hydroxylase activity in the striatum (Fleckenstein et al. 2009; Kita et al. 2009;
Little et al. 2009). Significantly, these effects are attenuated by pretreatment with antioxidants
(Kita et al. 2003).
In addition to dopaminergic oxidative stress, amphetamines also induce a
proinflammatory response that results in the activation of microglial cells. Microglia then release
TNFα and other molecules such as superoxide in an effort to damage pathogens (Guillot et al.
2008). Oxidative stress is further exacerbated by a decrease in the activity of mitochondrial
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complexes I, II, and IV in the striatum due to amphetamine use (Korpi et al. 2015). The
decreased activity of these complexes will result in decreased levels of ATP and more chances of
superoxide to be leaked out of the electron transport chain. In fact, dopaminergic cell damage
after amphetamine treatment can be prevented with superoxide dismutase an enzyme that targets
superoxide (Kita et al. 2009). Altogether, it appears that amphetamines can cause oxidative stress
to dopaminergic neurons resulting in dopamine cell loss and eventually in an overall decreased
level of DA and its related proteins.
Another psychostimulant, MPH, increases synaptic DA levels as high as amphetamines
(Little et al. 2009). Although repeated high doses of MPH were unable to produce the long-term
dopaminergic damage that is seen after repeated high doses of methamphetamine (Kita et al.
2009), MPH may be capable of increasing oxidative stress in the brain.

Oxidative Stress and Methylphenidate
Chronic MPH has been shown to induce oxidative stress and neuroinflammation in the
hippocampus of the rat brain by increasing lipid peroxidation and inflammatory cytokines and
decreasing GSH (Martins et al. 2006; Motaghinejad et al. 2016). Additionally, chronic, high dose
MPH was shown to deplete GSH and GSH reductase activity in the mitochondria in the
hippocampus of adult rats (Motaghinejad et al. 2016). Furthermore, chronic exposure to low (1
mg/kg) and high (10 mg/kg) doses of MPH led to an increase in inflammatory cytokines TNFα
and IL-1β and decreased the levels of BDNF and GDNF in the substantia nigra (SN), and that
this response sensitized DA neurons to further oxidative stress (Sadasivan et al. 2012).
Moreover, age appears to play a role in the extent of oxidative stress. Some labs have
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shown that young rats but not adults treated with chronic low (1 mg/kg or 2 mg/kg) doses of
MPH showed an increased index of DNA damage and lipid peroxidation in the striatum,
hippocampus, prefrontal cortex, and cerebellum (Andreazza et al. 2007; Comim et al. 2014;
Martins et al. 2006; Schmitz et al. 2012b). Additionally, acute MPH exposure increased
superoxide production in whole rat brain in young rats but not adult rats (Comim et al. 2014;
Gomes et al. 2009; Martins et al. 2006; Sadasivan et al. 2012). In contrast, some studies have
found that MPH did not induce oxidative stress and in some cases may protect against it.
Notably, low concentrations of MPH with methamphetamine appear to protect against the loss of
DA neurons due to blocking the DAT and preventing an influx of DA in to the cytosol (El Ayadi
and Zigmond 2011; Korpi et al. 2015; Little et al. 2009; Ludolph et al. 2006; Perfeito et al.
2013). Other studies were able to show that chronic exposure to MPH did not increase reactive
oxygen species in the blood of rats but did increase the activity of superoxide dismutase and
deplete total antioxidant capacity as determined by total radical-trapping antioxidant potential
(TRAP) (Schmitz et al. 2012a). When the hippocampus, striatum, prefrontal cortex and, cerebral
cortex of adult rats was analyzed, both acute and chronic exposure to MPH resulted in decreased
activity of all four complexes of the electron transport chain (Fagundes et al. 2010b). However,
in young rats, acute MPH appears to decrease the activity of mitochondrial complexes I and IV
in the cerebellum and prefrontal cortex but does not affect the striatum (Fagundes et al. 2010a).
In another study, chronic MPH exposure in young rats was found to increase the activity of
complexes III and IV and decrease the activity of complexes I and II (Comim et al. 2014).
Altogether, the effects of oxidative stress induced by MPH seem to depend on the dose used,
length of treatment, area of the brain studied, and age. Interestingly, dopamine-induced oxidative
stress and neurotoxicity has been linked to Parkinson’s disease, a neurodegenerative disorder,
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and individuals with a history of psychostimulant use have a higher rate of Parkinson’s disease
when compared to control populations (Curtin et al. 2015; Kita et al. 2009; Moratalla et al. 2017;
Perfeito et al. 2013).

Parkinson’s Disease
Parkinson’s disease was first described in 1817 by Dr. James Parkinson, who
characterized it as a shaking palsy (Emamzadeh 2017). Today, it is the second most common
neurodegenerative disorder, affecting 1% of the population over the age of 65 and 3.5% of
individuals 85 to 89 years old (Haddad et al. 2017; Zhang et al. 2019). Parkinson’s disease
pathology is characterized by dopaminergic cell loss in the substantia nigra pars compacta and
loss of dopaminergic input into the caudate and putamen nuclei of the striatum. The disease leads
to motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability.
Additionally, non-motor symptoms including impaired olfactory function, insomnia,
incontinence, depression, anxiety, and cognitive impairment (Klein et al. 2019; Zhang et al.
2019; Zucca et al. 2017). Motor symptoms are not seen until there is at least an 80% loss of
dopaminergic neurons in the substantia nigra, and they usually begin on one side of the body,
eventually affecting both sides (Emamzadeh 2017). However, non-motor symptoms can occur at
any stage of the disease and usually appear before motor symptoms (Emamzadeh 2017).
A distinguishing characteristic of Parkinson’s disease is the appearance of Lewy bodies
made up of aggregated α-synuclein (Asanuma et al. 2003; Dias et al. 2013; Villar-Piqué et al.
2016). In fact, as the disease progresses, α-synuclein levels are increased in the cerebral spinal
fluid and plasma of individuals with Parkinson’s disease as compared to controls (Emamzadeh
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2017). The appearance and increase in α-synuclein can be used to determine the stage of the
disease. Parkinson’s disease pathology of Lewy bodies has been proposed to occur in six stages,
known as Braak staging of Lewy pathology (Kalia and Lang 2015; Zucca et al. 2017). Stage one
begins with the appearance of α-synuclein aggregations in the peripheral nervous system,
olfactory bulbs, and medulla oblongata. The Lewy bodies will then proceed to affect the locus
coeruleus, caudal raphe nuclei, and magnocellular reticular formation in stage two. Stage three
begins five years before the onset of motor symptoms when the Lewy bodies begins to infiltrate
the substantia nigra, amygdala central subnucleus, pedunculopontine tegmental nucleus, and
Meynert’s nucleus. In stage four, individuals have lesions that extend to the temporal
mesocortex. After approximately ten years of motor symptoms, stage five is initiated when the
disease begins to affect tertiary sensory association areas and prefrontal cortex. Finally, in stage
six, secondary and primary motor and sensory areas are affected (Kalia and Lang 2015; Zucca et
al. 2017).
Most individuals develop idiosyncratic Parkinson’s disease; however, some individuals
develop familial Parkinsonism which is due to mutations in genes related to autophagy,
lysosomal function, oxidative stress response, and maintenance of mitochondrial integrity (Klein
et al. 2019). One such mutation is in the α-synuclein gene (SNCA gene) (Dias et al. 2013). As
mentioned earlier, α-synuclein normally associates with vesicular and membrane structures and
aids in the recycling and storage of neurotransmitters in synaptic vesicles (Dias et al. 2013;
Fleckenstein and Hanson 2003). Normally, α-synuclein is cleared by proteasomes, but mutant αsynuclein cannot be degraded by proteasomes and forms harmful aggregates (Dias et al. 2013;
Emamzadeh 2017; Monzani et al. 2019). When α-synuclein is not degraded, it can interfere with
cellular function, rendering dopaminergic neurons more susceptible to damage. As mentioned

50

earlier, conjugation of DA to α-synuclein inhibits the transition of protofibrils to fibrils, causing
an accumulation of toxic protofibrils (Dias et al. 2013; Monzani et al. 2019). Furthermore,
oxidative stress may also induce α-synuclein aggregation (Salim 2017). This may perpetuate the
problem as α-synuclein aggregation can negatively affect the structure and function of
mitochondria (Dias et al. 2013; Emamzadeh 2017). Specifically, α-synuclein can bind to the
inner mitochondrial membrane and associate with complex I, decreasing its activity and allowing
for more opportunities for superoxide to form (Dias et al. 2013). Relevant to this work, a variant
of the gene coding for α-synuclein is seen in individuals that have been diagnosed with both,
ADHD and Parkinson’s disease (Gerlach et al. 2019). Furthermore, the risk of developing
Parkinson’s disease before the age of fifty was increased in individuals with a history of using
psychostimulants to treat ADHD (Curtin et al. 2018; Walitza et al. 2007).
Additionally, age is a risk factor to developing Parkinson’s disease (Haddad et al. 2017;
Kordower et al. 2013; Zhang et al. 2019). In fact, natural aging leads to a 5 to 10% loss of
dopaminergic neurons every decade (Juarez Olguin et al. 2016; Salim 2017). However, within a
decade, individuals with Parkinson’s disease lose up to ten times more neurons than age-matched
controls (Lappin et al. 2018). Moreover, levels of the antioxidant, GSH decrease due to natural
aging, and the level is further decreased in age-matched individuals with Parkinson’s disease
(Bisaglia et al. 2010; Dias et al. 2013; Smeyne and Smeyne 2013). Fe levels have also been
observed to increase in the nigrostriatal pathway with natural aging, and Fe levels are further
increased in age-matched controls of individuals with Parkinson’s disease (Monzani et al. 2018;
Obata 2002; Sun et al. 2018). Depleted GSH and increased Fe levels provide the perfect
environment for the oxidation of DA. In fact, DA quinone-induced oxidative stress is considered
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one of the key factors leading to and exacerbating Parkinson’s disease (Bisaglia et al. 2010;
Cobley et al. 2018).
Interestingly, epidemiological studies relevant to this work also indicate that chronic use
of amphetamines appear to increase the risk of developing Parkinson’s disease (Curtin et al.
2015; Lappin and Sara 2019; Moratalla et al. 2017; Perfeito et al. 2013). In fact, one
epidemiological study found that methamphetamine users were 3.1 times more likely to develop
Parkinson’s disease (Curtin et al. 2015), and the median age of Parkinson’s disease onset was 6
years younger among chronic methamphetamine users (Lappin et al. 2018). Moreover, females
appear to have a greater risk of developing Parkinson’s disease after chronic exposure to
amphetamines than males (Curtin et al. 2015). This is particularly interesting, because the
disease is usually more prevalent in men than women (Kalia and Lang 2015). In general,
methamphetamine users can develop chronic deficits in fine motor dexterity and timed gait tasks,
and these effects can be seen in individuals who have been abstinent up to 12 months (Lappin et
al. 2018). Motor deficits with psychostimulant use are not unique to methamphetamine users,
chronic use of cocaine can also result in motor deficits. Some individuals that are known to have
abused MPH (26%) or cocaine (38%) develop punding (Fasano et al. 2008). Punding is when
individuals repeat a certain task compulsively with no purpose, a behavior that is often seen with
Parkinson’s disease. Additionally, chronic cocaine abusers are known to develop a resting tremor
that is associated with the degree and length of use (Brust 2010; Deik et al. 2012). Dystonia or
chorea has been observed with cocaine abuse; sometimes these symptoms do not appear until
after abstinence, and symptoms have been known to last up to twenty months after abstinence
(Brust 2010). Indeed, chronic psychostimulant use is associated with changes in the substantia
nigra, and this is a risk factor for movement disorders such as Parkinson’s disease (Mursaleen
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and Stamford 2016). Moreover, neurodegenerative changes in the nigrostriatal pathway can
occur with either methamphetamine or cocaine abuse. For example, DA levels in the striatum of
chronic methamphetamine users has been shown to be reduced by 50% (Brust 2010; Lappin et
al. 2018; Wilson et al. 1996), and loss of dopaminergic and serotonergic neurons are seen with
chronic use of methamphetamine, even after several years of abstinence (Mursaleen and
Stamford 2016). Neurodegenerative changes have also been seen in dopaminergic neurons of
chronic cocaine abusers, such as overexpression of α-synuclein (Deik et al. 2012; Illés et al.
2019). Additionally, cocaine is capable of binding to α-synuclein possibly leading to aggregation
(Illés et al. 2019). Decreased levels of DA and VMAT-2 are also seen with chronic abuse of
cocaine (Deik et al. 2012). Furthermore, post-mortem brain tissue of chronic cocaine users
showed decreased DA neuronal markers in the nigrostriatal pathway (Mursaleen and Stamford
2016). Lloyd and colleagues also observed this phenomena in mice (Lloyd et al. 2006).
However, this was not seen in other rodent studies (Lappin et al. 2018; Little et al. 2009).
Altogether, these studies suggest that chronic use of psychostimulants may have detrimental
effects on the nigrostriatal pathway, possibly leading to Parkinson’s disease.

Parkinsonian Toxin MPTP
In California, in the late 1970s and early 1980s a few unusual medical cases came to the
attention of neurologist, Dr. Langston. The patients in these cases were in a catatonic state unable
to move their muscles. They were even unable to speak. They displayed the classic symptoms of
Parkinson’s disease. However, the ages of the individuals ranged from 20 to 40 years old and
their symptoms developed into the advanced stages of Parkinson’s disease in a matter of days.
Parkinson’s disease is known to occur almost exclusively in the elderly, and the advanced stages
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take many years, if not decades, to develop. Dr. Langston gave his patients L-DOPA, and they
responded very well to the treatment and began to move again. Through careful detective work,
Dr. Langston soon discovered that the individuals had taken a new “synthetic heroin” and took
the next steps to acquire the product and analyze the compounds in the drug. The synthetic drug
contained meperidines. Among the meperidines found, the product contained 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) (Ballard et al. 1985). Dr. Langston soon discovered that
MPTP was capable of causing Parkinson’s disease-like symptoms in animal models too,
revolutionizing Parkinson’s disease research (Langston 2017; Palfreman 2014). Previously, there
had been no animal model for Parkinson’s disease. Interestingly, MPTP leads to changes in the
brain that are remarkably similar to the changes in the brain of individuals with Parkinson’s
disease.
Following systemic administration, MPTP crosses the blood-brain barrier. Then, glial
cells take up MPTP, where it is converted to MPP+ by monoamine oxidase B (MAO-B). MPP+ is
then taken up by DA neurons through the DAT, resulting in a number of effects that lead to
neurotoxicity (Blandini and Armentero 2012). In fact, mice that have a double knockout of DAT
are resistant to the toxic effects of MPTP (Little et al. 2009). Once inside the DA neurons, MPP +
inhibits complex I in the mitochondria and causes DA release, eventually leading to cell death.
The neurotoxicity is likely a result of oxidative stress produced by complex I inhibition and DA
release (Figure 1.7). Indeed, antioxidants can protect against MPP+ toxicity, and MPP+ has been
shown to cause lipid peroxidation and production of hydroxyl radicals (Lee et al. 2003; Obata
2002; Seyfried et al. 2000). However, in an effort to prevent toxicity, cells sequester MPP + into
vesicles. VMAT-2 helps move MPP+ into the vesicle, and VMAT-2 inhibitors and VMAT-2
heterozygote knockout mice have enhanced MPTP toxicity (Fleckenstein and Hanson 2003).
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However, MPP+ displaces DA from vesicles into the cytosol; therefore, it is possible that MPP +
may be capable of inducing oxidative stress by creating the right conditions for the autoxidation
of DA (Lee et al. 2003). In fact, MPP+ is known to instigate a large release of DA in the striatum
(Obata 2002). Moreover, MPP+ has a half-life of more than a week; therefore, MPP+ is capable
to causing a sustained release of DA (Obata 2002). As mentioned earlier, DA can easily form
free-radicals that lead to the formation of DA-o-quinones, further exacerbating oxidative stress.
GSH tries to protect against the oxidative stress produced by MPP+ and the DA release that it
produces but can become depleted (Gaki and Papavassiliou 2014; Seyfried et al. 2000).
MPTP has become a standard model for Parkinson’s disease for several reasons. Firstly,
MPTP leads to a significant loss of DA neurons in the nigrostriatal pathway, a hallmark
pathology of Parkinson’s disease. Furthermore, as discussed above, MPTP results in oxidative
stress, and studies show that oxidative stress also contributes to the development of Parkinson’s
disease (Hald and Lotharius 2005). In fact, post-mortem brains of Parkinson’s disease patients
have depleted GSH (Gaki and Papavassiliou 2014; Stokes et al. 2000). In addition, MPTP shares
a similar structure to the pesticide paraquat and a similar mechanism of action to the pesticide
rotenone, and pesticide exposure may contribute to idiopathic Parkinson’s disease (Drechsel and
Patel 2008; Gaki and Papavassiliou 2014). In fact, epidemiological studies indicate that
Parkinson’s disease is more prevalent in rural areas, where it is more likely that these pesticides
or similar compounds are used (Cerri et al. 2019). Furthermore, as mentioned earlier, α-synuclein
is implicated in Parkinson’s disease and aggregates of α-synuclein are seen after rodents are
exposed to the pesticides rotenone, dichlorvos, or paraquat (Dias et al. 2013). Interestingly,
single doses of MPTP do not result in Parkinson’s disease-like symptoms; however, PET studies
showed that asymptomatic individuals did have decreased dopaminergic neurons (Brust 2010).
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This suggests that multiple doses of the neurotoxin overtime, may eventually lead to a
neurodegenerative disorder. Moreover, males appear to be more susceptible to the neurotoxin,
MPTP.

Figure 1.7 MPTP mechanism of action. MPTP targets and destroys dopaminergic neurons,
resulting in Parkinson’s-like symptoms. MPTP crosses the blood-brain barrier, where it is
oxidized by MAO-B to MPP+ in glial cells. MPP+ is transported out of glial cells, where it is then
taken up by neurons through the dopamine transporter (DAT). MPP+ then inhibits complex I of
mitochondria, leading to apoptosis.
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Parkinson’s Disease, MPTP, and Gender
Parkinson’s disease has a higher prevalence in males than females (Kalia and Lang
2015). Furthermore, Parkinson’s disease affects males and females differently. For instance,
females tend to present with different motor symptoms, and motor symptoms appear later within
the disease progression when compared to males (Cerri et al. 2019; Picillo et al. 2017). Reduced
rigidity and tremor are often seen in females whereas males are more susceptible to developing
freezing gait (Cerri et al. 2019; Picillo et al. 2017). Nonmotor symptoms such as depression,
anxiety, fatigue, and loss of taste or smell are more common and more severe in females while
males are more likely to develop impulse control disorders such as pathological gambling and
hypersexuality (Cerri et al. 2019). It is hypothesized that differing levels of estrogen may be one
reason Parkinson’s disease affects males and females differently, because the incidence of
Parkinson’s disease is similar when males are compared to post-menopausal females (Cerri et al.
2019). Of note, both estrogen receptor α and estrogen receptor β are found in the substantia
nigra, and estrogen receptor β can be found on substantia nigra pars compacta projections to the
ventral striatum (Al Sweidi et al. 2012). Estrogen is believed to be neuroprotective in
Parkinson’s disease, and females with higher estrogen exposure throughout their lifetime have a
decreased risk of developing the disease (Cerri et al. 2019; Jurado-Coronel et al. 2018; Picillo et
al. 2017). Additionally, estrogen replacement therapy reduces the risk of developing Parkinson’s
disease and increases DAT density in the striatum of post-menopausal females (Al Sweidi et al.
2012; Jurado-Coronel et al. 2018). In contrast, administration of testosterone 24 hours before
methamphetamine increased DA depletion in the striatum of male mice and had no effect on
female mice (Jurado-Coronel et al. 2018).
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The most abundant estrogen in humans is 17 β-estradiol, which has been shown to
improve Parkinson’s disease symptoms for both males and females (Al Sweidi et al. 2012; Cerri
et al. 2019). The activity of 17 β-estradiol may be due to its modulation of DA and/or the DAT.
17 β-estradiol is capable of increasing the synthesis, release, reuptake, and turnover of DA (Al
Sweidi et al. 2012; Cerri et al. 2019; Morissette et al. 2008). Additionally, 17 β-estradiol is
known to modulate the levels of DAT in the striatum (Morissette et al. 2008). To illustrate, DAT
expression in the striatum of female mice was significantly increased during diestrus (low
estrogen) when compared to proestrus (high estrogen) (Jurado-Coronel et al. 2018). Furthermore,
there is a greater depletion of DA in the striatum when methamphetamine is administered during
the proestrus phase as compared to diestrus (Jurado-Coronel et al. 2018). One way that estrogen
may be neuroprotective is by modulating DAT levels (Ragonese et al. 2006). Of note, young to
middle-aged females have higher levels of DAT binding when compared to males, which may be
one possible reason pre-menopausal females are at a lower risk of developing Parkinson’s
disease (Jurado-Coronel et al. 2018).
Additionally, 17 β-estradiol has been shown to reduce oxidative stress and apoptosis in
Parkinson’s disease models (Cerri et al. 2019; Ragonese et al. 2006). The mitochondria of female
rats generally show less damage and oxidative stress than male rats in animal models of aging
and neurodegenerative disease (Cerri et al. 2019). This may be because neurons in females have
higher electron transport chain activity, which helps reduce the loss of superoxide radicals (Cerri
et al. 2019). Furthermore, estrogen is capable of decreasing DA-induced oxidative stress as it
plays a role in Fe metabolism, and males are more susceptible to Fe accumulation (Cerri et al.
2019). Furthermore, estrogens are known to prevent α-synuclein aggregation and, therefore,
prevent Lewy body formation (Picillo et al. 2017).
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Males appear to have an increased susceptibility to neurotoxicity induced by MPTP
(Jurado-Coronel et al. 2018; Morissette et al. 2008). Studies show that estrogen may be
responsible for conveying neuroprotection against MPTP. For example, MPTP caused a
significant decrease in dopaminergic neurons in the substantia nigra of ovariectomized female
mice, and this effect was attenuated with estrogen replacement (Jurado-Coronel et al. 2018).
Moreover, 17 β-estradiol was not neuroprotective against MPTP in estrogen receptor knock out
mice (Al Sweidi et al. 2012). However, estrogen may only be neuroprotective in females as
estrogen treatment in gonadectomized female mice decreased DA release in the striatum caused
by MPP+ but this effect was not seen in gonadectomized male mice (Disshon and Dluzen 2000).
In contrast, pretreatment with a low, physiological dose of estrogen before administering MPTP
yields neuroprotection to male and female mice, while a high dose of estrogen does not (Al
Sweidi et al. 2012; Morissette et al. 2008). Clearly, more research is needed to further elucidate
how mechanisms within the nigrostriatal pathway in females may differ from males.

Research Objectives
In recent years, ADHD has become an important health issue as more and more
individuals are diagnosed. Psychostimulants are first-line treatment, and MPH is the most
commonly prescribed drug to treat ADHD. MPH increases the levels of DA and NE in the
synapse by blocking DAT and NET, respectively. ADHD was initially thought to be a childhood
disorder and MPH was given for short periods of time; however, it is now thought to extend into
adulthood (Bonvicini et al. 2016). As a consequence, individuals are taking MPH for longer
periods of time, highlighting the need to study the chronic use of MPH. Additionally, since MPH
increases DA, it can be a drug of abuse. In this study, we analyzed the long-term consequences
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of exposure to low (therapeutic) and high (abusive) doses of MPH. MPH targets dopaminergic
neurons; therefore, chronic use of MPH may lead to changes within important dopaminergic
pathways, including the mesolimbic and nigrostriatal pathways. The mesolimbic pathway is
well-known for its role in reward; however, there are projections along this pathway that lead to
the hippocampus. The hippocampus plays an important role in memory and recall; and memory
and recall can be altered with MPH. In addition, adult neurogenesis is known to occur within the
dentate gyrus of the hippocampus. Mesolimbic dopaminergic neurons innervate the
hippocampus, and thus, it is possible that alterations in dopaminergic signaling may affect
neurogenesis. The nigrostriatal pathway is important for motor function. Indeed, a loss of the DA
neurons in this pathway leads to the movement disorder, Parkinson’s disease. The nigrostriatal
pathway is particularly vulnerable to oxidative stress due to its high concentration of
dopaminergic neurons. In fact, oxidative stress related to DA has been linked to the pathology of
Parkinson’s disease. When DA is at a physiological pH, it readily autoxidizes to form quinones
and free-radicals. These free-radicals can disrupt normal cellular function, possibly leading to
cell death. The mechanism of action of MPH leads to an increase of DA in the synaptic cleft;
since this increased DA may be oxidized to quinones and produce free-radicals, long-term MPH
exposure could increase oxidative stress. Therefore, we aimed to see if chronic MPH use
increased indicators of oxidative stress within the nigrostriatal pathway.
In Chapter 2, we investigate whether chronic low or high doses of MPH affect the
proliferation and survival of granule cells within the DG of the hippocampus. To investigate the
proliferation and survival of newly generated cells after chronic MPH treatment, we utilized 5’ethinyl-2’-deoxyuridine (EdU), a thymidine analog which incorporates into DNA when the cell
is dividing. Number of EdU+ cells to total neurons, which were labeled using
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immunohistochemistry for neuronal nuclei (NeuN), were calculated and compared between
groups. Interestingly, chronic low and high doses of MPH were found to increase hippocampal
neurogenesis rate. However, if MPH injections were not continued, then the newly generated
cells did not survive. If treatment was continued, the newly generated neurons survived only in
the mice receiving low dose methylphenidate.
To investigate the mechanism for this effect, we examined levels of proteins linked to
cell proliferation in the hippocampus, including BDNF, GDNF, VEGF, TrkB, and beta-catenin
after chronic MPH treatment. BDNF and GDNF were investigated in the dentate gyrus of the
hippocampus using ELISA-based assays. BDNF and GDNF levels were not significantly
different between groups. The protein levels of VEGF, TrkB, and beta-catenin were determined
using a Simple Western assay. Hippocampal VEGF, TrkB, and beta-catenin were significantly
increased in mice receiving low dose MPH for 28 days compared to controls. Interestingly, high
dose MPH significantly decreased beta-catenin after 28 days and decreased VEGF, beta-catenin,
and TrkB after 56 days compared to controls. Thus, low dose MPH appears to increase cell
proliferation and cell survival in the hippocampus, and these effects may be mediated by
increases in VEGF, TrkB, and beta-catenin. While high dose MPH may initially increase
neuronal proliferation, newly-generated neurons are unable to survive long-term, possibly due to
decreases in VEGF, TrkB and beta-catenin.
In Chapter 3, we examine the mechanism by which long-term MPH exposure sensitizes
nigrostriatal DA neurons to the Parkinsonian toxin, MPTP. We hypothesized that chronic MPH
exposure leads to an increase in DA-o-quinone production and a depletion in the antioxidant
GSH. To investigate this, male mice received chronic low or high dose MPH or saline and were
then challenged with MPTP or saline. The striatum was extracted, and DA-o-quinone levels was
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examined using near-infrared fluorescence dot blots, while a glutathione assay was used to
measure glutathione content. DA o-quinone formation increased with increasing doses of MPH.
Additionally, MPH dose-dependently resulted in a depletion of glutathione, which was further
depleted following treatment with the Parkinsonian toxin, MPTP. Thus, the increased sensitivity
of dopamine neurons to MPTP toxicity following chronic MPH exposure may be due, at least in
part, to quinone production and subsequent depletion of glutathione.
In Chapter 4, we investigated the interaction between long-term MPH exposure and
MPTP in a female model. We hypothesized that chronic exposure to MPH will render
dopaminergic neurons within the nigrostriatal pathway more sensitive to MPTP, and that
estrogen may play a protective role. To investigate this, female mice received chronic low or
high dose MPH or saline and were then challenged with MPTP or saline. Female mice were
grouped and analyzed as either proestrus (high estrogen) or anestrus (low estrogen) at the time of
MPTP (or saline) exposure. Animals were sacrificed 7 days after MPTP or saline exposure, and
midbrain tissue was sectioned, immunostained for tyrosine hydroxylase, and the number of
dopaminergic neurons in the substantia nigra were counted using stereology. In addition, as
above, the striatum was extracted, and oxidative stress related to increased dopamine levels was
examined using a glutathione assay to measure glutathione content and near-infrared
fluorescence to measure free and protein-bound ortho-quinones. Interestingly, dopaminergic
neurons in the nigrostriatal pathway are sensitized to MPTP in female mice that are in proestrus
at the time of MPTP exposure. However, anestrus females exhibited no neurotoxicity to MPTP
after long-term exposure to MPH. This same trend was observed in proestrus females that
received long-term MPH, but MPTP effect was not significant. Chronic MPH exposure
contributed to GSH depletion, but surprisingly, it did not increase dopamine quinone levels or
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dopaminergic cell loss. There were no significant differences in anestrus animals, with the
exception of a depletion in glutathione seen when animals received long-term high dose (10
mg/kg) MPH followed by MPTP. Thus, estrogen may sensitize neurons to MPTP in this model,
and long-term MPH may contribute to glutathione depletion within the striatum. This study
provides insight into how long-term psychostimulant use may affect males and females
differently.
Altogether, these studies have shown that chronic treatment with MPH is changes
neuronal viability and plasticity in multiple dopaminergic pathways. Chronic MPH at low and
high doses affects mesolimbic DA input to the hippocampus, altering neurogenesis within the
dentate gyrus. Additionally, chronic MPH treatment sensitizes dopaminergic neurons in the
nigrostriatal pathway to further oxidative stress, possibly leading to neurodegeneration.
Moreover, chronic MPH treatment appears to affect males and females differently, possibly due
to estrogen. These data are particularly relevant as there are an estimated 35 million stimulant
users worldwide (Lappin et al. 2018). Furthermore, many of these stimulant users are children
diagnosed with ADHD (Sridhar et al. 2017). Importantly, these data indicate that long-term MPH
may have profound effects on adolescent brain development. Therefore, knowledge gained about
the chronic use of MPH can be used to make more informed decisions on the length of treatment
for individuals with ADHD.
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Abstract
Methylphenidate is a psychostimulant used to treat Attention Deficit Hyperactivity Disorder.
Neurogenesis occurs throughout adulthood within the dentate gyrus of the hippocampus and can
be altered by psychoactive medications; however, the impact of methylphenidate on
neurogenesis is not fully understood. We investigated the effects of chronic low (1 mg/kg) and
high (10 mg/kg) intraperitoneal doses of methylphenidate on neurogenesis in mouse
hippocampus following 28 days and 56 days of treatment. Interestingly, methylphenidate, at both
doses, increased neurogenesis. However, if methylphenidate treatment was not continued, the
newly generated cells did not survive after 28 days. If treatment was continued, the newly
generated neurons survived only in the mice receiving low dose methylphenidate. To investigate
the mechanism for this effect, we examined levels of proteins linked to cell proliferation in the
hippocampus, including brain-derived neurotrophic factor (BDNF), glial cell line-derived
neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF), tropomyosin receptor
kinase B (TrkB), and beta-catenin. BDNF or GDNF levels were not significantly different
between groups. However, hippocampal VEGF, TrkB, and beta-catenin were significantly
increased in mice receiving low dose methylphenidate for 28 days compared to controls.
Interestingly, high dose methylphenidate significantly decreased beta-catenin after 28 days and
decreased VEGF, beta-catenin, and TrkB after 56 days compared to controls. Thus, low dose
methylphenidate appears to increase cell proliferation and cell survival in the hippocampus, and
these effects may be mediated by increases in VEGF, TrkB, and beta-catenin. While high dose
methylphenidate may initially increase neuronal proliferation, newly-generated neurons are
unable to survive long-term, possibly due to decreases in VEGF, TrkB and beta-catenin.
Keywords: Neurogenesis, Methylphenidate, Hippocampus, Dentate Gyrus
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Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobehavioral developmental
disorder that affects 11% of children ages 4-17 years old in the U.S. alone (Hamed et al., 2015).
The most commonly prescribed drug to treat ADHD is methylphenidate (MPH; Ritalin®). MPH
is a psychostimulant that inhibits dopamine (DA) and norepinephrine (NE) reuptake, increasing
the amount of these monoamines in the synaptic cleft. MPH inhibits the reuptake of these
monoamines by blocking dopamine or norepinephrine transporters (DAT and NET) but has a
greater affinity for DAT than NET. Recently, there has been an increase in the number of high
school and college students abusing MPH and an increase in children continuing to take MPH
for ADHD symptoms into adulthood (Bonvicini et al., 2016). Despite the increasing use and
abuse of MPH, few studies have been conducted that examine the neurologic effects of chronic
treatment with MPH.
Neurogenesis or the “birth of new neurons” occurs throughout life within the subgranular
zone (SGZ) of dentate gyrus (DG) of the hippocampus, where the newly generated cells become
incorporated into the local DG as granular cells. The rate of hippocampal neurogenesis as well as
the survival of these cells is known to be altered by exposure to psychoactive compounds, such
as psychostimulants and antidepressants (Lee et al., 2012). Antidepressants such as selective
serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and
drugs that block only the NET increase neurogenesis, increasing both proliferation and survival
of hippocampal neurons. In contrast, chronic exposure to cocaine, a psychostimulant that inhibits
the DAT, NET, and the serotonin transporter (SERT), has been shown to either increase or
decrease neurogenesis rate, depending on the animal model (Castilla-Ortega et al., 2016; GarcíaFuster et al., 2010; Lloyd et al., 2010; Sudai et al., 2011). In one study, chronic cocaine exposure
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(2 x 10 mg/kg/day, subcutaneous injections) for 28 days increased hippocampal neurogenesis
rate in mice (Lloyd et al., 2010). In another study, rats trained to self-administer cocaine (1.5
mg/kg intravenous infusions) for 14 days displayed impaired neurogenesis, with decreases in cell
proliferation, yet no effect on cell survival (Sudai et al., 2011). Thus, given the number of
serotonin, norepinephrine, and dopamine-targeting drugs that alter cell proliferation within the
hippocampus, these monoamine neurotransmitters appear to play a modulatory role in
hippocampal neurogenesis. This idea is further supported by studies demonstrating that lesions
of noradrenergic fibers projecting to the dentate gyrus decrease hippocampal neurogenesis
(Aimone et al., 2014). Other studies support a role for DA in hippocampal neurogenesis;
specifically, immunohistochemical analyses of the hippocampus have shown areas of dense
dopaminergic afferent fibers within the DG where the DA receptor, D2 is expressed (Srikumar et
al., 2011). Activation of D2 receptors increases adult neurogenesis and stabilizes memory, while
blockade of the D2 receptors or lesions of dopaminergic afferent fibers leads to a decrease in
neurogenesis and impairs memory (Aimone et al., 2014; McNamara et al., 2014; Srikumar et al.,
2011). Given the substantial evidence for the role of NE and DA in both hippocampal
development and plasticity, it is likely that chronic exposure to MPH, a NET and DAT inhibitor,
could influence neurogenesis in the dentate gyrus.
The monoamines DA and NE may modulate hippocampal neurogenesis by a number of
mechanisms, which may include regulation of proteins known to affect cell proliferation,
including beta-catenin and vascular endothelial growth factor (VEGF). Other NET and DAT
inhibitors have been shown to affect neurogenesis within the hippocampus via upregulating
expression of these proteins (Rolando and Taylor, 2014; Warner-Schmidt and Duman, 2007;
Zhao et al., 2008). Beta-catenin is a downstream effector of the Wnt pathway, which mediates
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the proliferation of neuronal progenitor cells (Warner-Schmidt and Duman, 2006) and is
important for the normal development of the hippocampus (Rolando and Taylor, 2014; Yu et al.,
2014). When beta-catenin expression is inhibited, there is a decrease in hippocampal
neurogenesis (Hui et al., 2015; Mostany et al., 2008; Rolando and Taylor, 2014). Moreover,
antidepressants that block the reuptake of NE stimulate proliferation of quiescent neuronal
progenitor cells in the adult hippocampus through activation of the Wnt pathway (Rolando and
Taylor, 2014). Additionally, beta-catenin signaling is known to stimulate the synthesis of VEGF
(Hui et al., 2015). VEGF and its receptors are expressed in and on neuronal progenitor cells,
neurons, glial cells, and endothelial cells in the hippocampus, where VEGF appears to promote
neurogenesis. Antidepressants, which again are known to increase neurogenesis, induce
increases in VEGF, and the blockade of VEGF signaling inhibits the neurogenic effects of
antidepressants (Cao et al., 2004; Zhao et al., 2008). Finally, direct infusion of VEGF into the
hippocampus increases neurogenesis (Warner-Schmidt and Duman, 2007; Zhao et al., 2008).
Another growth factor that is known to promote neurogenesis in the hippocampus is
brain-derived neurotrophic factor (BDNF), and some studies have indicated that MPH can alter
expression of BDNF and/or its receptor, TrkB (Fumagalli et al., 2010). SSRIs and SNRIs known
to increase hippocampal neurogenesis also cause an increase in BDNF in the hippocampus of
rodent models of depression and in post-mortem human brain tissue from individuals who had
been treated with antidepressants (Jiang et al., 2014; Sairanen et al., 2005; Tayyab et al., 2018).
BDNF has a high affinity for TrkB, and this receptor is expressed in neural progenitor cells of
the dentate gyrus (Li et al., 2008). TrkB is required for hippocampal neurogenesis, and deletion
of TrkB from neuronal progenitor cells impairs neurogenesis (Li et al., 2008). Chronic
antidepressant treatment upregulates mRNA of BDNF and TrkB in the hippocampus (Sairanen et
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al., 2005), and infusion of BDNF into the hippocampus of rats increases neurogenesis within the
dentate gyrus (Scharfman et al., 2005). Of note, natural aging leads to a decrease in adult
neurogenesis, and this decline is associated with decreases in TrkB expression, while BDNF
levels are unchanged (Aimone et al., 2014). Interestingly, there is evidence for a modulatory role
of BDNF by Wnt signaling, as beta-catenin signaling promotes synthesis of BDNF, and
upregulation of BDNF has been found to increase the growth of neurons in culture through
activation of the Wnt pathway (Tayyab et al., 2018). Another neurotrophic factor thought to be
involved in hippocampal neurogenesis is glial cell line-derived neurotrophic factor (GDNF).
Antidepressants increase GDNF mRNA expression in rat astrocytes in vitro (Kajitani et al.,
2012), and infusion of GDNF into the hippocampus of rats in vivo increases neurogenesis within
the dentate gyrus (CHEN et al., 2005). Thus, MPH and other drugs that influence monoamine
neurochemistry may influence hippocampal neurogenesis through altering the expression of
these proteins.
Despite the extensive use of MPH and the supporting evidence that this NET/DAT
inhibitor may influence neurogenesis, few studies have examined the impact of this drug on
hippocampal plasticity (Lagace et al., 2006; Lee et al., 2012; Schaefers et al., 2009; van der
Marel et al., 2015). Furthermore, the studies that have been conducted are conflicting. In some
models, treatment with MPH appears to increase neurogenesis (Lee et al., 2012; van der Marel et
al., 2015), while others reveal that the number of proliferating neurons in the hippocampus is not
altered with MPH (Lagace et al., 2006; Schaefers et al., 2009). Additionally, in one study, a
decrease in survival of newly generated neurons was seen in adult rats that were exposed to MPH
as juveniles (Lagace et al., 2006). These conflicting results and the overwhelming evidence that
MPH can alter neurogenesis highlights a need for further study. Here, we examine how treatment
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with chronic MPH affects the proliferation and survival of granule cells within the DG of the
hippocampus.

Materials and Methods
Mice and Drug Treatment
All experiments and procedures with animals were performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals, and protocols were approved by the
University Committee on Animal Care (UCAC) at East Tennessee State University. Juvenile
male Swiss-Webster mice were acclimated to the animal facility for a week prior to treatment.
Mice were allowed food and water ad libitum and were kept on a 12-hour light/dark cycle.
Beginning at post-natal day 28 (PND 28), the mice received intraperitoneal (i.p.) injections twice
daily with saline, 1 mg/kg, or 10 mg/kg MPH (Sigma Aldrich, dissolved in 0.9% sterile saline)
for 28 or 56 days, ending at PND 56 or PND 84, respectively. Five animals were included in
each treatment group for both 28 and 56 days of treatment. This period would correspond with
the time of early adolescence (PND 28) through late adolescence (PND 56) or adulthood (PND
84) (Laviola et al., 2003). As doses of less than 5 mg/kg MPH i.p. in rodents may model the use
of MPH in the clinical treatment of ADHD (Gerasimov et al., 2000; Koda et al., 2010), the 1
mg/kg MPH dose was considered therapeutic. In contrast, the high dose of 10 mg/kg MPH i.p.
may represent recreational misuse or the use of MPH in the treatment of narcolepsy (Valvassori
et al., 2007). The injections were administered using a school week (5 days/week) dosing
schedule to prevent MPH from impeding normal weight gain and/or growth (Martins et al., 2004;
Roche et al., 1979).
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EdU injections and Immunohistochemistry
After 28 days of treatment with saline, 1 mg/kg, or 10 mg/kg MPH, all mice received a
single i.p. dose of 50 mg/kg EdU. EdU is a thymidine analog that is incorporated into DNA
during cell division (Chehrehasa et al., 2009). In order to examine neurogenesis rate, some mice
were sacrificed 1 day after EdU injection, whereas survival of newly generated cells was
examined by sacrificing other mice 28 days after EdU injection. Of note, in order to determine
how MPH affects the survival, during the 28 days post-EdU, 1 group received no injections of
saline or MPH, while the other group continued injections of saline or MPH. Mice were
sacrificed via transcardial perfusion with saline, followed by 4% paraformaldehyde, and brain
tissue was subsequently collected. Brains were removed and placed in cryoprotectant (30%
sucrose in phosphate buffer) and then sectioned on the cryostat at 20 µm and collected onto
slides. Tissue sections were then stained for EdU using Click-iT EdU Alexa Fluor 594 imaging
kit (Molecular Probes) and double-labeled for the neuronal marker, NeuN using
immunohistochemistry (1:400 mouse anti-NeuN (Millipore) and 1:750 AlexaFluor 488 Goat
anti-Mouse (Molecular Probes). Approximately 20 slides were made from each animal with 6
sections per slide. Every other slide was taken and double-labeled for EdU and NeuN.
Sections were analyzed using an epifluorescence microscope (Olympus BX41) equipped with an
Olympus Q-color 3 digital camera and Q-Cap Pro 7 software (Fig. 2.1). The number of EdU
positive cells were counted in the subgranular zone of the dentate gyrus, and the number of
NeuN positive cells were counted throughout the dentate gyrus. The ratio of Edu positive cells/
NeuN positive cells were calculated for each section and total ratios were compiled for each
brain/mouse. Counts were made in both hemispheres at 200 X, averaged, and compared between
the groups.
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Analysis of proteins related to cell proliferation in the hippocampus
The expression of proteins known to influence cell proliferation in the hippocampus were
examined following chronic exposure to saline, 1 mg/kg, or 10 mg/kg MPH; these included
brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF),
vascular endothelial growth factor (VEGF), tropomyosin receptor kinase B (TrkB), and betacatenin. For these analyses, mice were sacrificed by decapitation, and the hippocampus was
removed, flash-frozen in liquid nitrogen, and stored at -70°C until analysis. The hippocampal
tissue was homogenized in lysis buffer (300 µl/2 mg of tissue) and normalized for protein
content following a Bradford protein assay. The quantification of BDNF and GDNF in the
hippocampus utilized an enzyme-linked immunosorbent assay (ELISA, Boster Biological
Technology, Pleasanton, CA). The protein levels of VEGF, TrkB, and beta-catenin were
determined using a Protein Simple, Simple Western assay (anti-rabbit HRP 12-230 included with
kit or anti-goat HRP, 1:50, R&D Systems). The antibodies rabbit anti-VEGF (0.5 µg/mL,
Millipore), goat anti-TrkB (10 µg/mL, R&D Systems), and goat anti-beta-catenin (50 µg/mL,
R&D Systems) were utilized, and the samples were normalized to GapdH expression (rabbit
anti-GapdH, 1:1000, Novus). The protocol included with the kit was followed with no
deviations. The Compass software (Protein Simple, Simple Western) was run on its default
settings.
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Figure 2.1 Representative fluorescent photomicrographs of the hippocampal dentate gyrus from
mice receiving saline (a & b), 1 mg/kg MPH (c & d), or 10 mg/kg MPH (e & f). The brain
sections were stained to identify the neuronal marker NeuN (green) seen in panels c, d, & e and
the newly generated EdU positive cells (red) seen in b, d, & f
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Statistical Analysis
Descriptive statistics were completed on all data and are reported as means +/- SEM. All
Statistical analysis were performed using multiple variable analysis of variance (ANOVA),
followed by Tukey’s multiple comparisons test using GraphPad Prism software version 5. P
values of < 0.05 were considered significant.

Results
Chronic Exposure to MPH Increases Neurogenesis
In order to examine the effect of chronic MPH on neurogenesis rate, mice receiving
saline, 1 mg/kg, or 10 mg/kg MPH were injected with EdU, and brains were collected the
following day. The ratio of EdU+ cells to NeuN+ cells were calculated and compared between
groups. Interestingly, both the low and high doses of MPH significantly increased neurogenesis
rates compared to saline control (Fig. 2.2). In fact, ratios were approximately 5-fold greater
following chronic MPH exposure, indicating that chronic exposure of MPH markedly increases
neurogenesis in the DG.
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Figure 2.2 Chronic MPH exposure increases in neurogenesis within the dentate gyrus (DG). The
ratios of EdU+ cells/ NeuN+ cells in the DG of the hippocampus were compared in mice
receiving saline, 1 mg/kg, or 10 mg/kg MPH, injected with EdU, and brains collected 1 day later.
Data are expressed as means ± SEM (n=5) and were subjected to a one-way ANOVA followed
by Tukey’s post-hoc analyses, *p=0.0306 vs Saline

Survival of Newly Generated Neurons is Drug and Dose-Dependent
To determine if the new cells created in response to MPH exposure survive and are
incorporated into the DG, mice receiving saline, 1 mg/kg, or 10 mg/kg MPH were injected with
EdU, and brains were collected 28 days later. In one experiment, mice did not continue to
receive treatment during the 28 days post-EdU and were kept in standard housing (Fig. 2.3a). In
the second experiment, mice continued to receive twice-daily injections 5 days/week per their
treatment group (saline, 1 mg/kg, or 10 mg/kg MPH). Again, the ratios of EdU+ to NeuN+ cells
were calculated and compared. There were no significant differences between any of the groups
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in mice where treatment was discontinued, indicating that the new neurons “born” as a result of
MPH exposure do not survive and integrate into the DG (Fig. 2.3a). Furthermore, when
treatment was continued during the 28 days following EdU exposure, a significant difference in
EdU+/NeuN+ ratios was only seen with the low (1 mg/kg) dose of MPH (Fig. 2.3b). Mice
receiving chronic exposure to high dose (10 mg/kg) MPH had EdU+/NeuN+ ratios that were
equivalent to control animals. However, again, there still appears to be a loss of cells as ratios in
1 mg/kg MPH mice were only about 2-fold higher than saline-controls (as compared to 5-fold
higher 1-day post-EdU). Thus, although both low and high doses of MPH may increase
neurogenesis rate, neurons are maintained and incorporated into the DG only in mice who
continue to receive low dose MPH and not all cells survive.

Figure 2.3 Survival of newly generated hippocampal neurons following chronic MPH exposure.
The ratios of EdU+ cells/NeuN+ cells in the dentate gyrus of the hippocampus were compared in
mice receiving saline, 1 mg/kg, or 10 mg/kg MPH, injected with EdU, and brains collected 28
days later. a) Newly generated hippocampal neurons do not survive when MPH is not continued.
b) The newly generated neurons survive when only therapeutic doses of MPH are continued. All
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data are expressed as means ± SEM (n=5) and were subjected to one-way ANOVA followed by
Tukey’s post-hoc analyses, *p=0.0413 vs Saline, #p=0.0333 vs 1 mg/kg MPH

Chronic Exposure to MPH and Growth Factors
In order to elucidate the mechanism by which MPH influences neurogenesis rate and
survival of neurons in the hippocampus, we examined the protein levels of various neurotrophic
factors in the hippocampus following chronic MPH exposure. Given the wealth of evidence for
the role of BDNF, GDNF, and VEGF, we performed ELISA-based assays to examine
hippocampal BDNF and GDNF levels and simple westerns to examine levels of VEGF.
Surprisingly, there were no significant differences in BDNF and GDNF between any of the drug
groups (Fig. 2.4a and 2.4b). However, BDNF does appear to increase with age in all treatment
groups. After 28 days of exposure to 1 mg/kg MPH, VEGF was increased compared to the saline
group. Conversely, there were no significant differences in hippocampal VEGF in mice exposed
to 10 mg/kg MPH despite the profound effect of this dose on neurogenesis rate. Additionally, in
mice treated to the match the neuronal survival experiments (28 days treatment, followed by an
additional 28 days of treatment = 56 days treatment), VEGF was significantly decreased in mice
receiving the high (10 mg/kg) dose of MPH compared to both saline and low dose (Fig. 2.4c).
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Figure 2.4 Hippocampal growth factors following chronic MPH. Protein levels of BDNF (a),
GDNF (b), and VEGF (c). Data are expressed as means ± SEM (n=5). One-way ANOVA
followed by Tukey’s post-hoc analysis, *p<0.05 vs 28 Days Saline (p=0.0076 28 Days Saline vs
28 Days 1 mg/kg MPH, p=0.0311 28 Days Saline vs 56 Days 10 mg/kg MPH), #p<0.05 vs 56
Days 10 mg/kg MPH (p=0.0001 56 Days 10 mg/kg MPH vs 28 Days 1 mg/kg MPH, p=0.0476
56 Days 10 mg/kg MPH vs 28 Days 10 mg/kg MPH, p=0.0046 56 Days 10 mg/kg MPH vs 56
Days Saline, p=0.0005 56 Days 10 mg/kg MPH vs 56 Days 1 mg/kg MPH)

Chronic Exposure to MPH and Proteins: TrkB and Beta-catenin
To further investigate the mechanism by which MPH influences neurogenesis rate and
neuronal survival, we examined the levels of a number of other proteins known to modulate
hippocampal neurogenesis, including the BDNF receptor, TrkB. While no significant differences
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were seen in BDNF (Fig. 2.4a), the expression of its receptor appears to be influenced by MPH.
Following 28 days of 1 mg/kg MPH, TrkB is significantly increased in the hippocampus
compared to saline-control animals. However, a decrease in hippocampal TrkB was observed in
mice receiving 10 mg/kg MPH for both 28 days and 56 days (Fig. 2.5).

Figure 2.5 Protein levels of the BDNF receptor, TrkB normalized to GapdH. Data are expressed
as means ± SEM (n=5). One-way ANOVA followed by Tukey’s post-hoc analysis, *p=0.0148 vs
28 Days Saline, **p<0.0001 vs 28 Days 1 mg/kg MPH, #p=0.0003 vs 56 Days 1 mg/kg MPH

Given the considerable evidence for the role of the Wnt pathway in hippocampal
neurogenesis, we examined an important downstream effector of this pathway, beta-catenin.
Notably, after 28 days of 1 mg/kg MPH, beta-catenin was significantly increased compared to
levels in saline-control animals; however, there are no significant differences between saline and
1 mg/kg MPH after 56 days of treatment. Similar to the pattern seen with TrkB, animals that
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received 10 mg/kg MPH for either 28 or 56 days had significantly less hippocampal beta-catenin
than animals that received either saline or 1 mg/kg MPH (Fig. 2.6).

Figure 2.6 Protein levels of beta-catenin normalized to GapdH. Data are expressed as means ±
SEM (n=5). One-way ANOVA followed by Tukey’s post-hoc analysis, *p<0.05 vs 28 Days
Saline (p=0.0389 28 Days Saline vs 1 mg/kg MPH, p=0.0184 28 Days Saline vs 10 mg/kg
MPH), #p<0.0001 vs 28 Days 1 mg/kg MPH, **p=0.0010 vs 56 Days Saline, ##p=0.0068 vs 56
Days 1 mg/kg MPH

Discussion
The present study examined how exposure to chronic MPH at low and high doses can
induce changes in neurogenesis within the DG from childhood to adulthood, in vivo. We
demonstrated that both low and high doses of MPH increase neurogenesis, as indicated by
increased EdU+/NeuN+ neuron ratios 1-day post EdU exposure. However, the survival of the
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newly divided neurons 28 days later is drug- and dose-dependent. Chronic exposure to low doses
of MPH appears to support the maintenance and integration of the new neurons into the
hippocampus, as EdU+/NeuN+ ratios in animals exposed to low dose MPH were significantly
higher than controls. However, chronic exposure to high doses of MPH does not have the same
effect, as EdU+/NeuN+ ratios 28 days after EdU exposure were not significantly different than
controls. Additionally, newly generated neurons do not survive if MPH is not continued.
Previous studies of the effect of MPH on hippocampal neurogenesis produced mixed
results. Studies have shown that low, oral doses (2.5 or 5 mg/kg) of MPH given to adolescent
mice for 21 days have no impact on the rate of neurogenesis, but high doses (10 mg/kg) increase
hippocampal neurogenesis compared to controls (Lee et al., 2012). Others have shown an
increase in neurogenesis when adolescent rats were treated orally with MPH at low (5 mg/kg) or
high (10 mg/kg) doses for 28 days (van der Marel et al., 2015). In contrast, one study noted a
decrease in survival of newly generated neurons into adulthood in rats exposed to MPH as
adolescents (Lagace et al., 2006). Other studies showed that MPH had no effect on neurogenesis
in rats when administered i.p. for 15 days (2 mg/kg MPH) or gerbils when administered orally
for 30 days (5 mg/kg MPH) (Lagace et al., 2006; Schaefers et al., 2009). These seemingly
conflicting observations are likely due to differences in the length of treatment, doses of MPH,
drug delivery, and animal model.
The growth factors BDNF, GDNF and VEGF have been shown to effect neurogenesis
within the DG (Cao et al., 2004; Fumagalli et al., 2010; Kirby et al., 2015; Lee et al., 2012;
Warner-Schmidt and Duman, 2007, 2006). We investigated these proteins in our model and have
shown that the mechanism by which MPH increases neurogenesis does not appear to involve
BDNF or GDNF. In this study, MPH, at neither low nor high doses, induced a change in BDNF
81

or GDNF. Although no previous studies investigated the effect of MPH on GDNF expression,
studies examining the effect of MPH on BDNF have been mixed. While some groups observed
increases in BDNF expression in the hippocampus, others have reported a decrease in BDNF
expression with MPH exposure (Fumagalli et al., 2010; Lagace et al., 2006; Lee et al., 2012).
Previous studies have shown increases in BDNF in the subgranular zone with 10 mg/kg (Lee et
al., 2012), an increase in BDNF in the striatum with 1 mg/kg (Fumagalli et al., 2010), and a
decrease in BDNF in the hippocampus using a 2 mg/kg dose of MPH (Lagace et al., 2006).
Another study shows a decrease in BDNF mRNA in the hippocampus of juvenile rats, and an
increase in adult rats treated with MPH (Banerjee et al., 2009). Additionally, MPH has been
shown to decrease BDNF and TrkB in the prefrontal cortex and increase BDNF in the striatum
(Fumagalli et al., 2010). These differences may be due to the dose of MPH, animal model, and
the area of the brain studied.
In this study, VEGF, TrkB, and beta-catenin were significantly increased by low dose
MPH after 28 days compared to saline-treated animals, correlating to the increase in the rate of
neurogenesis seen in the DG after 28 days of 1 mg/kg MPH. Interestingly, although exposure to
high doses (10 mg/kg) of MPH for 28 days induced an increase in neurogenesis rate, none of
these factors were increased in response to 28 days of exposure to 10 mg/kg MPH. In fact, there
was a significant decrease in beta-catenin after 28 days and a significant decrease in VEGF, betacatenin, and TrkB was observed after 56 days of treatment. Of note, the decreased expression of
these proteins may explain why neurons generated in response to 10 mg/kg MPH were unable to
survive, with or without continued treatment, 28 days later. Although BDNF was unaltered by
methylphenidate (only increased by age), TrkB was decreased by high dose MPH. Other studies
have seen no change in BDNF and a decrease in TrkB with natural aging (Aimone et al., 2014).
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Chronically, low doses of MPH appear to increase cell proliferation and cell survival in
the hippocampus, and these effects may be mediated by increases in the expression of VEGF,
TrkB, and beta-catenin. While chronic high doses of MPH may initially increase neuronal
proliferation, newly-generated neurons are unable to survive long-term, possibly due to
decreases in VEGF, TrkB and beta-catenin. Neurogenesis is capable of improving cognitive
function (Villeda et al., 2011), and the ability of MPH to impact hippocampal neurogenesis may
play an important role in the mechanism by which MPH increases cognitive functions.
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Abstract
Background: Methylphenidate (Ritalin®) is a psychostimulant used chronically to treat attention
deficit hyperactivity disorder. Methylphenidate acts by preventing the reuptake of dopamine and
norepinephrine, resulting in an increase in these neurotransmitters in the synaptic cleft. Excess
dopamine can be autoxidized to a quinone that may lead to oxidative stress. The antioxidant,
glutathione helps to protect the cell against quinones via conjugation reactions; however,
depletion of glutathione may result from excess quinone formation. Chronic exposure to
methylphenidate appears to sensitize dopaminergic neurons to the Parkinsonian toxin 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We hypothesized that oxidative stress caused by
the autooxidation of the excess dopamine renders dopaminergic neurons within the nigrostriatal
pathway to be more sensitive to MPTP.

Methods: To test this hypothesis, male mice received chronic low or high doses of MPH and
were exposed to saline or MPTP following a 1-week washout. Quinone formation in the striatum
was examined via dot blot, and striatal GSH was quantified using a glutathione assay.

Results: Indeed, quinone formation increased with increasing doses of methylphenidate.
Additionally, methylphenidate dose-dependently resulted in a depletion of glutathione, which
was further depleted following MPTP treatment.
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Conclusions: Thus, the increased sensitivity of dopamine neurons to MPTP toxicity following
chronic methylphenidate exposure may be due to quinone production and subsequent depletion
of glutathione.

Keywords: Methylphenidate, Oxidative stress, Glutathione, Dopamine quinone
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Introduction
According to the Centers for Disease Control and Prevention, 6.4 million children have
been diagnosed with attention deficit hyperactivity disorder (ADHD) in the U.S. alone. The
psychostimulant, methylphenidate (MPH) is the most commonly prescribed drug for the
treatment of ADHD. MPH acts by blocking dopamine (DA) and norepinephrine (NE)
transporters, preventing the reuptake of these catecholamines following release. Thus, MPH
causes a profound, acute increase in DA levels within the striatum (STR) [1]. Previous research
has shown that chronic exposure to MPH causes dopaminergic neurons within the nigrostriatal
pathway to be more sensitive to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) [2]. These findings are supported by epidemiological data that
indicates use of psychostimulants, such as amphetamine and methamphetamine, increases the
risk of developing Parkinson’s disease [3-5]. Of note, a significant loss of dopaminergic neurons
within the nigrostriatal pathway is a hallmark of this disease. Given that oxidative stress is
known to be involved in the degenerative process of Parkinson’s disease [6] and that excess
dopamine may cause oxidative stress [7], we hypothesize that chronic MPH exposure leads to
oxidative stress when the autoxidation of excess DA renders dopaminergic neurons within the
STR to be more sensitive to MPTP.
At a physiological pH, the hydroxyl group in DA is able to dissociate, creating DA oquinone. Thus, DA can be autoxidized without catalysis, producing DA o-quinone which cycles
to aminochrome and eventually forms hydrogen peroxide (H2O2) (Figure 3.1). The H2O2 may be
converted to superoxide and hydroxyl radicals in the presence of the metal ions, leading to
oxidative stress (Figure 3.1). In addition to this, excess DA that is not sequestered in vesicles can
form the DA o-quinone in the presence of metal ions and enzymes with peroxidase activity.
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Interestingly, ferrous ions appear to accumulate in the nigrostriatal pathway, promoting
catecholamine oxidation [8]. Fortunately, neurons have systems in place to combat this potential
source for oxidative stress. Glutathione (GSH) is an important antioxidant that protects against
the toxicity of quinones via conjugation reactions, and the resulting molecules may be
incorporated into neuromelanin or released into the cerebral spinal fluid [9]. The cofactor,
NADH is needed in the conjugation reaction between GSH and DA o-quinone. Unfortunately,
GSH is competing with the cyclization product of DA o-quinone, aminochrome for NADH.
Aminochrome uses NADH to form leukoaminochrome o-semiquinone radical and hydroxyl
radicals (Figure 3.1) [10]. Therefore, excess quinone may deplete GSH as well as deplete the
cofactor needed for the conjugation reaction. When GSH is depleted, neurons are vulnerable to
oxidative stress and therefore, neurotoxicity. Additionally, the quinone forms thiol conjugates
with sulfhydryl groups on cysteine residues that disrupt normal functioning of proteins including
glucocerebrosidase and parkin, proteins known to be associated with Parkinson’s disease [8]. In
addition to damaging proteins, DA o-quinone and other reactive oxygen species are able to
induce oxidative stress by lipid peroxidation and DNA oxidation leading to further damage of the
neuron and eventually, apoptosis.
Some laboratories have investigated the potential for MPH to induce oxidative stress.
Chronic MPH has been found to decrease GSH content in the several brain regions [9]. No
studies have examined the production DA quinone and subsequent depletion of GSH in the STR
following chronic MPH. Given the fact that the STR is rich in dopaminergic neurons and
implicated in Parkinson’s disease, we measured the amount of quinones and GSH in the STR
following chronic MPH treatment.
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Figure 3.1 Dopamine oxidation pathway. Dopamine can be oxidized to dopamine o-quinone.
Glutathione (GSH) then conjugates with dopamine o-quinone and degrades to form 5-S-cysteinyl
dopamine. 5-S-cysteinyl dopamine is then incorporated into neuromelanin or released into the
cerebral spinal fluid. GSH can also conjugate with aminochrome and is then incorporated into
neuromelanin. Neurotoxicity results when superoxide and/or hydroxyl radicals are formed and is
exacerbated when GSH is depleted.
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Materials and Methods
Mice and Drug Treatment
All experiments and procedures with animals were performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals, and protocols were approved by the
University Committee on Animal Care (UCAC) at East Tennessee State University. Mice were
acclimated to the animal facility for a week prior to treatment. Mice were allowed food and
water ad libitum and were kept on a 12-hour light/dark cycle. Adolescent male Swiss-Webster
mice received intraperitoneal injections twice daily of saline, 1, or 10 mg/kg MPH for 12 weeks
using a school week (5 days/week) dosing schedule per the previous study [2]. Swiss-Webster
mice were chosen due to their resistance to MPTP [11]. After 12 weeks, all animals were
subjected to drug washout for 7 days to prevent MPH competing with MPTP at DA transporters.
Then, half of each group was treated with MPTP (4 x 20 mg/kg, every 2 hours), while the other
half was administered 4 injections of sterile saline. Seven days after the MPTP injection, mice
were sacrificed by decapitation, and the striatum was removed, flash-frozen in liquid nitrogen,
and stored at -70°C until analysis. An n of 4 mice was used for each group.

Quinone Assay
The amount of catechol-derived ortho-quinones in the STR was quantified using nearinfrared fluorescence (nIRF) dot blots [12]. Samples were homogenized in 300 µL of cold PBS
by sonication, centrifuged for 5 minutes at 4°C at 400 x g and supernatant discarded. Free and
protein-bound ortho quinones were then extracted 3 times using the following procedure. Pellets
were resuspended in cold lysis buffer then incubated for 30 minutes in an ice-water slurry.
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Samples were then frozen and thawed 3 times and then centrifuged for 30 minutes at 4°C at
100,000 x g. Supernatant was saved as the triton-soluble extraction and the triton-pellet was used
for the second extraction. The triton-pellet was resuspended in SDS lysis buffer, boiled for 10
minutes, sonicated and boiled for another 10 minutes and then centrifuged for 30 minutes at
22°C at 100,000 x g. Supernatant was saved as the SDS-soluble extraction and the SDS-pellet
was used for the third extraction. The SDS-pellet was resuspended in 1 N sodium hydroxide
(NaOH) and incubated overnight at 55°C. The samples were then speed-vacuumed and
resuspended in base buffer and saved as NaOH-soluble extraction. A standard curve was
prepared using DOPAC oxidized with equimolar sodium periodate. Each sample extraction and
standard were dot blotted onto a membrane and allowed to dry in a fume hood. Each extraction
was normalized for protein content following a BCA protein assay. Dot blots were scanned at
700 nm on the Odyssey Infrared Imaging System (li-Cor).

Glutathione Assay
GSH content in the STR was measured using a GSH assay kit (Cayman Chemical Co.).
Briefly, tissues were homogenized in 50 mM phosphate buffer (10 ml/g of tissue) on ice and
centrifuged (10,000 g for 15 minutes at 4°C). The supernatant was removed and incubated for 5
minutes at room temperature with 10% metaphosphoric acid (v/v) and then centrifuged at 2,000
g for 3 minutes. Supernatant was removed again and normalized for protein content following a
Bradford protein assay. Samples were added to a 96-well plate and mixed with the reagent
cocktail provided in the GSH assay kit and described in the protocol with no deviations,
incubated for 25 minutes in the dark, and the absorbance was determined at 414 nm.
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Statistics
Data are reported as means +/- SEM. All statistical analyses were performed using a
multiple variable analysis of variance (ANOVA), followed by Fisher’s multiple comparisons
tests using Minitab 17 software. P values of less than 0.05 were considered significant.

Results and Discussion
Increased Quinone Formation after Chronic MPH
MPH dose-dependently increased ortho-quinone production in the STR (Figure 3.2).
Notably, high dose MPH increased quinone production by nearly 1,700 fold compared to saline
+ saline and a 9-fold increase compared to 1 mg/kg MPH + saline. In animals treated with
MPTP, there were no significant differences between drug groups; however, there was a trend
towards increasing quinone formation with increasing doses of MPH (Figure 3.2). Interestingly,
although MPTP increased quinone formation compared to saline-treated animals (p < 0.05 Saline
+ Saline vs. Saline + MPTP), there appears to be an overall decrease in quinone formation in
MPH-MPTP-treated animals compared to MPH-saline-treated animals. Although MPTP is
known to acutely increase DA release and eventually induce oxidative stress, the oxidative stress
results in DA neurotoxicity in vulnerable animal models [13]. In a previous study using the same
model, chronic MPH followed by MPTP resulted in a significant increase in sensitivity to MPTP,
as evidenced by a decrease in dopaminergic cell bodies in the SN [2]. Thus, following long-term
MPH, even in MPTP-resistant animals, it is likely that DA and thus, DA quinone will be
depleted in the terminals 7 days following exposure. Given MPTP neurotoxicity is widely
recognized as retrograde toxicity, it is likely that damage to terminals was even greater than the
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cell body loss previously reported. While several studies have shown that MPH causes oxidative
damage in the brain [9, 14, 15], to our knowledge this is the first study to show an increase in
quinones with MPH exposure.

Figure 3.2 Total free and protein-bound ortho-quinones in the STR. Swiss-Webster mice
received intraperitoneal injections of saline, 1, or 10 mg/kg MPH for 12 weeks followed by
either saline or MPTP. Data are expressed as means ± SEM (n=4). One-way ANOVA followed
by Fisher’s post-hoc test. (n = 4) *p < 0.05 vs. Saline + Saline; ##p < 0.05 vs. 1 mg/kg MPH +
Saline
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Glutathione Depletion after Chronic MPH
GSH is an important antioxidant found throughout the CNS that has been shown to
protect neurons from excess DA quinone formation [16-18]. GSH conjugates with quinones,
preventing radical formation (Figure 3.1) [18]. In order to further elucidate if oxidative stress
was related to DA oxidation, we measured the GSH content in the STR, as an increase in
quinone formation should result in a depletion of GSH. Indeed, MPH dose-dependently depleted
GSH in the STR (Figure 3.3). These data are consistent with studies that observed a decrease in
GSH in the hippocampus, striatum, and prefrontal cortex with MPH exposure [9]. Additionally,
MPTP caused GSH depletion in the STR, with the greatest depletion of GSH occurring in high
dose (10 mg/kg) MPH animals exposed to MPTP (Figure 3.3). This is consistent with previous
animal studies [9], and the discovery that GSH is depleted in post-mortem brains of Parkinson’s
disease patients [19]. Overall, the implications of GSH depletion are significant, because DA
toxicity is enhanced when GSH is depleted [17].
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Figure 3.3 Glutathione content in the STR. Swiss-Webster mice received intraperitoneal
injections of saline, 1, or 10 mg/kg MPH for 12 weeks followed by either saline or MPTP. Data
are expressed as means ± SEM. One-way ANOVA followed by Fisher’s post-hoc test (n = 4). *p
< 0.05 vs. Saline + Saline

Conclusion
This study is the first to show a dose-dependent increase in striatal quinone production
following chronic MPH exposure. The increased quinone formation with chronic MPH exposure
is accompanied by a depletion in striatal GSH, with a greater depletion in animals exposed to the
Parkinsonian toxin MPTP. Thus, it is likely that chronic elevations in DA resulting from longterm MPH result in the oxidation of DA to the DA quinone. In an effort to protect neurons from
potential oxidative stress, the DA quinone is conjugated to GSH. However, over time, GSH
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becomes depleted, leaving cells vulnerable to oxidative stress. Thus, following long-term MPH
exposure, nigrostriatal neurons become more sensitive to the Parkinsonian toxin, MPTP. These
findings lend mechanistic insight to epidemiological studies that indicate chronic
psychostimulant use increases the risk of developing Parkinson’s disease [3, 4, 7, 9, 14, 15].
Alarmingly, medications for ADHD are being prescribed for longer periods of time, sometimes
from childhood into adulthood [20]. Unfortunately, chronic MPH exposure may predispose
individuals who are treated with these psychostimulant medications to the development of
Parkinson’s disease later in life.
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Abstract
Methylphenidate (MPH) is the most commonly prescribed drug for the treatment of
ADHD in males and females. However, a majority of previous studies investigated the effect of
MPH in only males, and little is known regarding consequences of female exposure to MPH.
This is unfortunate because the few studies that have been conducted indicate females have a
greater sensitivity to MPH. Previous research in male mice has shown that chronic exposure to
MPH causes dopaminergic neurons within the nigrostriatal pathway to be more sensitive to the
Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). However, estrogen
has been shown to protect dopaminergic neurons from MPTP neurotoxicity. Therefore, in this
study, we test the hypothesis that chronic MPH exposure in female mice will render
dopaminergic neurons in the nigrostriatal pathway more sensitive to MPTP, and that estrogen
may play a protective role. Interestingly, proestrus females exhibited greater sensitivity to
MPTP, with significantly reduced dopaminergic neurons in the SN and significant increases in
DA quinone production. Chronic MPH exposure contributed to GSH depletion, but surprisingly,
it did not increase dopamine quinone levels or dopaminergic cell loss. There were no significant
differences in anestrus animals, with the exception of a depletion in GSH seen when animals
received chronic high dose (10 mg/kg) MPH followed by MPTP. Thus, estrogen may actually
sensitize neurons to MPTP in this model, and chronic MPH may contribute to GSH depletion
within the striatum. This study provides insight into how chronic psychostimulant use may affect
males and females differently.

Keywords: Methylphenidate, Dopamine, Oxidative stress, Glutathione, Dopamine quinone,
Estrogen
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Introduction
The Centers for Disease Control and Prevention (CDC) reports that as of 2016, 6.1
million children have been diagnosed with attention deficit hyperactivity disorder (ADHD) in the
United States alone (Danielson et al. 2018). Methylphenidate (MPH) is the most commonly
prescribed drug for the treatment of ADHD, and many children receive MPH from childhood to
early adulthood; yet, most of the scientific literature focuses on understanding short-term
consequences of MPH. As such, it is extremely important to examine the long-term
consequences of MPH exposure. Additionally, the preponderance of previous studies
investigated the effect of methylphenidate in only males, and little is known regarding
consequences of female exposure to MPH. This is unfortunate due to the fact that the few studies
that have been conducted indicate females have a greater sensitivity to MPH (Brown et al. 2012).
Additionally, females have been shown to have higher brain concentrations of MPH than males
(Bentley et al. 2015). The therapeutic effect of MPH is due to its ability to increase the amount of
dopamine (DA) and norepinephrine (NE) in the synaptic cleft by blocking DA and NE
transporters. Interestingly, there are sex differences reported in regard to dopaminergic tone
(Cummins et al. 2014; Frolich et al. 2014). For example, in the striatum, females have a higher
concentration of DA transporters, and higher concentrations of DA release when compared to
males (Walker et al. 2006). Furthermore, females have a greater DA turnover rate than males.
The increased DA turnover rate has been shown to be estrogen dependent, because an
ovariectomy reduces the DA turnover rate and estrogen restores it (Dluzen et al. 1996). DA
release in the striatum can be increased when ovariectomy mice are treated with estrogen
(Dluzen et al. 1996). Moreover, natural fluctuations of estrogen in the estrous cycle are capable
of altering the activity of DA in the striatum (Dluzen et al. 1996).
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At a physiological pH, DA is capable of autoxidizing by dissociation of a hydroxyl
group, creating a DA o-quinone. This unstable DA o-quinone then cyclizes to an aminochrome,
which is reduced to leukoaminochrome o-semiquinone radicals, forming H2O2 and hydroxyl
radicals. In addition to autoxidation, iron and copper, as well as enzymes with peroxidase
activity are capable of catalyzing DA conversion to DA o-quinone, speeding up the reaction and
increasing the levels of DA o-quinones (Klein et al. 2019). DA o-quinones are capable of
disrupting normal cell function by forming adducts with cysteine residues and inducing oxidative
stress throughout the cell (Monzani et al. 2018; Park et al. 2007). Interactions with cysteine
residues can be particularly harmful to cell viability as cysteine residues are often found at the
active site of enzymes. To prevent DA oxidation, excess DA is normally sequestered in vesicles
with a lower pH (Klein et al. 2019). However, since MPH is capable of increasing the
concentration of DA in the synaptic cleft, it may allow for excess free DA to autoxidize and
produce reactive oxygen species. Furthermore, estrogen is thought to play a protective role
against oxidative stress, as an increase in oxidative stress was seen in ovariectomy mice, and
estrogen was able to decrease the oxidative stress (Gaignard et al. 2015).
Fortunately, our brains are capable of quickly removing small amounts of DA o-quinone
by using a natural antioxidant, glutathione (GSH) (Motaghinejad et al. 2016). In fact, GSH has
been shown to prevent DA-induced cell death in a number of models (Park et al. 2007; Stokes et
al. 2000; Zhou and Lim 2009). GSH forms conjugation reactions with quinones or
aminochromes, eventually leading to the formation of 5-S-cysteinyl DA or 4-S-glutathionyl-5,6dihydroxyindoline, respectively. 5-S-cysteinyl DA and 4-S-glutathionyl-5,6-dihydroxyindoline
may then be incorporated into neuromelanin (Zhou and Lim 2009), and some 5-S-cysteinyl DA
is released into cerebral spinal fluid. However, GSH can become depleted when there is excess
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quinone production. If GSH is depleted, there are more free quinones, and therefore more free
radicals, leading to oxidative stress and eventually neurotoxicity via apoptosis (Stokes et al.
2000). An estimated 80% of the DA in the brain is found within the nigrostriatal pathway (Golan
D 2011; Stahl 2008). The primary responsibility of neurons within this pathway is purposeful
movement, and damage to this pathway can result in tremors, spasms, tardive dyskinesia, and
Parkinson’s disease (Klein et al. 2019). Therefore, drugs, such as MPH, that increase synaptic
DA levels may have detrimental effects on the nigrostriatal pathway. In fact, MPH has been
shown to induce oxidative stress by forming DA o-quinones and depleting GSH in the
hippocampus and nigrostriatal pathway (Martins et al. 2006; Motaghinejad et al. 2016; Oakes et
al. 2019).
Previous research in male mice has shown that chronic exposure to MPH causes
dopaminergic neurons within the nigrostriatal pathway to be more sensitive to the Parkinsonian
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Sadasivan et al. 2012). MPTP
produces an experimental model of Parkinson’s disease by causing a significant loss in DA
neurons within this pathway. Furthermore, our lab has previously shown a dose-dependent
increase in quinone formation in the striatum of male mice following chronic exposure to MPH
(Oakes et al. 2019). Moreover, the increase in quinone formation in the striatum was
accompanied by a depletion of GSH, and the depletion of GSH was enhanced when male mice
were additionally exposed to MPTP (Oakes et al. 2019). Of note, estrogen has been found to be
neuroprotective against MPTP, and it is thought that estrogen conveys neuroprotection by
modulating the DA transporter (Dluzen et al. 1996). Interestingly, chronic use of
psychostimulants appears to increase the risk of developing Parkinson’s disease (Curtin et al.
2015; Moratalla et al. 2017; Perfeito et al. 2013). Although estrogen has been shown to be
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protective against MPTP (Dluzen et al. 1996), human epidemiological studies have demonstrated
that the use of stimulant drugs puts females at a greater risk of developing neurodegenerative
disorders (Curtin et al. 2015). In contrast, estrogen is capable of working synergistically with
psychostimulants, increasing the interactions between the psychostimulant and DA reward
system (Curtin et al. 2015). Therefore, in this study, we test the hypothesis that chronic MPH
exposure in female mice will render dopaminergic neurons in the nigrostriatal pathway more
sensitive to MPTP, and that estrogen may play a protective role.

Materials and Methods
Mice and Drug Treatment
Experiments and procedures with the animals were performed following the regulations
set forth by the NIH Guide for the Care and Use of Laboratory Animals. The protocols followed
were approved by the University Committee on Animal Care (UCAC) at East Tennessee State
University. Mice were allowed food and water ad libitum and were kept on a 12-hour light and
dark cycle. Adolescent female Swiss-Webster (MPTP-resistant (Heikkila 1985)) mice received
intraperitoneal (i.p.) injections of saline, 1, or 10 mg/kg MPH (Sigma Aldrich, dissolved in 0.9%
sterile saline) for 12 weeks. A dose of 1 mg/kg MPH was used because doses of less than 5
mg/kg MPH i.p. in rodents may represent the clinical treatment of ADHD (Gerasimov et al.
2000; Koda et al. 2010). In contrast, a dose of 10 mg/kg MPH i.p. was chosen as it may represent
recreational misuse or use of MPH treatment in narcolepsy (Valvassori et al. 2007). Injections
were administered using a school week (5 days/week) dosing schedule to prevent weight loss
(Martins et al. 2004; Roche et al. 1979). Female mice were allowed to enter the estrus cycle as
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normal. The Whitten effect was used on the day of the last MPH injection by introducing male
pheromones into half the cages prompting female mice to enter the estrus cycle at the same time
(Gangrade and Dominic 1984; Whitten 1957). Half of the cages had no pheromones introduced
keeping the female mice in anestrus via the Lee-Boot effect (Ma et al. 1998). Female mice were
either in proestrus or anestrus 7 days after the last MPH injection, which was confirmed by
vaginal smear (McLean et al. 2012).

MPTP Dosing in Female Swiss-Webster Mice

Previous work has indicated that different strains of mice can have varied sensitivity to
MPTP (Boyd et al. 2007; Hamre et al. 1999; Heikkila 1985; Hoskins and Davis 1989; Sedelis et
al. 2000; Sonsalla and Heikkila 1988; Sundström et al. 1987; Vidyadhara et al. 2017). SwissWebster mice have been found to be MPTP-resistant and thus, this strain is useful in examining
changes in sensitivity to this Parkinsonian toxin. There is an established protocol for
administration of MPTP (4 x 20 mg/kg, i.p.) in male Swiss-Webster mice (Hamre et al. 1999;
Heikkila 1985). In addition, there appears to be differences in sensitivity to MPTP depending on
gender (Alam et al. 2016; Disshon and Dluzen 2000; Dluzen et al. 1996; Sedelis et al. 2000).
However, the use of the MPTP model for Parkinson’s has been limited in female models, and
none of these studies used female Swiss-Webster mice as a model for MPTP. Therefore, the
appropriate MPTP dose for female Swiss-Webster mice was determined by analyzing the
survival rate at 4 different doses of MPTP. Anestrus female mice were challenged with injections
of MPTP 4 times every 2 hours. The MPTP doses given were 10 mg/kg, 12.5 mg/kg, 15 mg/kg,
or 20 mg/kg. The probability of survival was calculated based on the number survived in a group
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divided by the total of the group. Each of the 4 groups had an n of 5. After this preliminary
experiment, a dose of 12.5 mg/kg was chosen and utilized for the remaining work. Briefly, after
the 12 weeks of MPH treatment, all animals were subjected to drug washout for 7 days, and then
half of each group were treated with MPTP 4 times every 2 hours (12.5 mg/kg), while the other
half was administered 4 injections of sterile 0.9% saline. Seven days after the MPTP injection,
mice were sacrificed.

Immunohistochemistry
Mice were sacrificed via transcardial perfusion with saline, followed by 4%
paraformaldehyde. The brains were then removed, embedded in paraffin, and serially sectioned
at 10 µm from the rostral hippocampus to the cerebellar-midbrain junction. Serial sections were
mounted 5 sections per slide onto polyionic slides (Superfrost-plus, Fisher Scientific).
Deparaffinized slides were incubated with an antibody against tyrosine hydroxylase to identify
DA neurons (mouse monoclonal anti-tyrosine hydroxylase, Sigma-Aldrich;1∶500 and
biotinylated mouse IgG; 1:1000). A diaminobenzindine (DAB) reaction was used to yield a
brown color to mark TH-expressing DA neurons. All tissue sections were counter stained with
the nissl stain Neutral Red for landmark identification. TH-positive neurons and TH-negative,
Nissl-positive cells within the pars compacta region of the substantia nigra (SNpc) that had the
characteristics of dopaminergic neurons were counted using a 40x objective (total magnification
400x). Specifically, neurons from both left and right sides of the SNpc within one section per
slide (chosen randomly and then maintained throughout all sections, (i.e. the 3rd section on each
slide) were counted). TH positive neurons within the SNpc were counted and numbers estimated
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using the Abercrombie correction factor as reported previously (Sadasivan et al. 2012). An n of 3
to 5 mice was used for each group.

Quinone Assay
Mice were sacrificed by decapitation, and the striata were removed, flash-frozen in liquid
nitrogen, and stored at -70°C until analysis. An n of 4 to 5 mice was used for each group. The
amount of free and protein bound ortho-quinones in the striatum was quantified using nearinfrared fluorescence (nIRF) dot blots (Mazzulli et al. 2016). As reported previously samples
were homogenized in 300 µL of cold PBS by sonication, centrifuged for 5 minutes at 4°C at 400
x g and supernatant discarded. Free and protein-bound ortho quinones were then extracted 3
times using the following procedure. Pellets were resuspended in cold lysis buffer then incubated
for 30 minutes in an ice-water slurry. Samples were then frozen and thawed 3 times and then
centrifuged for 30 minutes at 4°C at 100,000 x g. Supernatant was saved as the triton-soluble
extraction and the triton-pellet was used for the second extraction. The triton-pellet was
resuspended in SDS lysis buffer, boiled for 10 minutes, sonicated and boiled for another 10
minutes and then centrifuged for 30 minutes at 22°C at 100,000 x g. Supernatant was saved as
the SDS-soluble extraction and the SDS-pellet was used for the third extraction. The SDS-pellet
was resuspended in 1 N sodium hydroxide (NaOH) and incubated overnight at 55°C. The
samples were then speed-vacuumed and resuspended in base buffer and saved as NaOH-soluble
extraction. A standard curve was prepared using DOPAC oxidized with equimolar sodium
periodate. Each sample extraction and standard were dot blotted onto a membrane and allowed to
dry in a fume hood. Each extraction was normalized for protein content following a BCA protein
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assay. Dot blots were scanned at 700 nm on the Odyssey Infrared Imaging System (li-Cor)
(Oakes et al. 2019).

Glutathione Assay
GSH content in the striatum was measured as previously stated (Oakes et al. 2019). A
GSH assay kit (Cayman Chemical Co.) was utilized. Briefly, tissues were homogenized in 50
mM phosphate buffer (10 ml/g of tissue) and centrifuged (10,000 g for 15 minutes at 4°C). The
supernatant was removed and incubated for 5 minutes at room temperature with 10%
metaphosphoric acid (v/v) and then centrifuged at 2,000 g for 3 minutes. Supernatant was
removed again and normalized for protein content following a Bradford protein assay. Samples
were added to a 96-well plate and mixed with the reagent cocktail provided in the GSH assay kit
and described in the protocol with no deviations, incubated for 25 minutes in the dark, and the
absorbance was determined at 414 nm.

Statistical Analysis
Data are reported as means +/- SEM and the statistical analyses were performed using
multiple variable analysis of variance (two-way ANOVA), followed by Tukey’s multiple
comparisons test using GraphPad Prism software version 8. An n of 3 to 5 mice was used for
each group. P values of < 0.05 were considered significant.
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Results
MPTP Treatment in Female Swiss-Webster Mice
As mentioned previously, there is an established protocol for administration of MPTP (4
x 20 mg/kg, i.p.) in male Swiss-Webster mice (Hamre et al. 1999; Heikkila 1985). However,
when we administered MPTP according to this protocol, 100% of the female Swiss-Webster
mice died. Many died after the second and third injections, with the remaining mice dying
shortly after the last injection. Previous work with other strains of mice (such as MPTP-sensitive
C57 mice) have also shown complete lethality when female mice were given the same dose as
males (4 x 20 mg/kg, i.p.) (Schwarting et al. 1999). While some peripheral toxicity is expected
with MPTP, it is clear that female mice require MPTP dose adjustments. As such, we performed
a preliminary experiment whereby we tested various doses of MPTP to determine the maximal
dose we could use that would allow for at least 50% survival. As above, all doses were given 4
times, every two hours and included 20 mg/kg, 15 mg/kg, 12.5 mg/kg, and 10 mg/kg. The 20
mg/kg dose again produced a 100% death rate, and 15 mg/kg produced an 80% death rate. With
a dose of 12.5 mg/kg, the death rate was 50%, and with 10 mg/kg, the death rate was 40%. Thus,
for the remaining experiments, a dose of 12.5 mg/kg MPTP, every 2 hours for a total of 4
injections, was utilized.

Dopamine Cell Count in the Substantia Nigra
We conducted a stereological analysis of TH+ cells within the SNpc in order to determine
how chronic MPH followed by saline/MPTP affected numbers of dopaminergic neurons within
that brain region. Females were further subdivided based on the stage of the estrus cycle at the
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time of MPTP exposure, as proestrus animals have high estrogen levels and anestrus animals
have low estrogen levels. Interestingly, in proestrus females exposed to chronic saline treatment,
MPTP caused a significant decrease in the number of dopaminergic neurons within the SNpc
(Fig. 4.1m). This is surprising given the dose is lower than doses used in males, and these mice
are typically MPTP-resistant (Hamre et al. 1999). Although this trend was observed in animals
exposed to chronic MPH, there were no significant differences. Additionally, there were no
significant differences observed in anestrus animals across any of the treatments (Fig. 4.1n).
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Fig. 4.1 Representative images of the substantia nigra par compacta (SNpc) of proestrus female
mice treated with saline (a-d), 1 mg/kg (e-h), or 10 mg/kg (i-l) MPH for 12 weeks followed by
MPTP. Stereological estimates of dopaminergic neuron numbers in the SNpc of proestrus (m) or
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anestrus (n) female mice. Female Swiss-Webster mice received intraperitoneal injections of
saline, 1, or 10 mg/kg MPH for 12 weeks (labeled at the bottom of the bar graph) followed by
either saline (black bars) or MPTP (gray bars). Female mice were confirmed to be in proestrus or
anestrus at the time of the injection, and tissue was collected 7 days later. Data are expressed as
means ± SEM (n = 3 to 5). Two-way ANOVA followed by Tukey’s post-hoc analyses

Dopamine O-Quinone Formation in the Striatum
Dopamine may contribute to neurotoxicity when it oxidizes to a DA o-quinone. As such,
we quantified levels of quinones within the terminal region of the nigrostriatal pathway, the
striatum. The production of DA o-quinones was significantly increased in proestrus mice that
were exposed to chronic saline followed by MPTP compared to those exposed only to saline
(Fig. 4.2a). Interestingly, again, no significant differences were observed in proestrus mice
exposed to chronic MPH followed by MPTP or saline. Moreover, no significant differences were
observed among anestrus subgroups (Fig. 4.2b). However, anestrus mice exposed to chronic
saline followed by MPTP displayed significantly lower dopamine quinone production compared
their proestrus counterparts (Fig. 4.2a and 4.2b)
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Fig. 4.2 The concentration of free and protein-bound ortho-quinones in the striata of proestrus (a)
or anestrus (b) female mice. Female Swiss-Webster mice received intraperitoneal injections of
saline, 1, or 10 mg/kg MPH for 12 weeks followed by either saline or MPTP. Female mice were
confirmed to be in proestrus or anestrus at the time of the injection. Data are expressed as means
± SEM (n = 4 to 5). Two-way ANOVA followed by Tukey’s post-hoc test. *p<0.05 vs. proestrus
saline + MPTP

Glutathione Concentration in the Striatum
GSH is an important antioxidant within the CNS that can conjugate to DA orthoquinones in an effort to prevent formation of free radicals. Thus, subsequently, we quantified
striatal GSH levels in proestrus and anestrus subgroups following chronic saline or MPH
exposure, followed by saline or MPTP. Interestingly, in proestrus females, a significant decrease
in GSH levels was observed following chronic exposure to both low (1 mg/kg) and high (10
mg/kg) doses of MPH (Fig. 4.3a). Furthermore, mice exposed to chronic MPH followed by
MPTP displayed even greater depletion in GSH levels, with mice receiving 10 mg/kg MPH
followed by MPTP having the lowest levels. In anestrus females, chronic MPH did not deplete
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GSH, but when chronic MPH animals also received MPTP, there was a significant depletion in
GSH levels within the striatum (Fig. 4.3b)

Fig. 4.3 Glutathione (GSH) concentration in the striata of proestrus (a) or anestrus (b) female
mice. Female Swiss-Webster mice received intraperitoneal injections of saline, 1, or 10 mg/kg
MPH for 12 weeks followed by either saline or MPTP. Female mice were confirmed to be in
proestrus or anestrus at the time of the injection. Data are expressed as means ± SEM (n = 3 to
5). Two-way ANOVA followed by Tukey’s post-hoc test. *p<0.05 vs. proestrus saline + saline,
**p<0.05 vs. proestrus saline + MPTP

Discussion
Previously, we found that chronic MPH increased quinone formation and depleted GSH
in the striatum of male Swiss-Webster mice, and MPTP caused an even greater depletion in GSH
(Oakes et al. 2019). In this study, we examined the effect of chronic MPH exposure in female
Swiss-Webster mice on dopaminergic neurons in the nigrostriatal pathway and whether or not
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those dopaminergic neurons became sensitive to the neurotoxin, MPTP. We also investigated the
role estrogen may play by utilizing the estrus cycle. Firstly, we elucidated the appropriate MPTP
dose for female Swiss-Webster mice. Swiss-Webster mice are known to be MPTP-resistant
(Heikkila 1985), and estrogen has been shown to be neuroprotective (Dluzen and Horstink 2003;
McArthur and Gillies 2011). Unfortunately, when female Swiss-Webster mice are administered
the typical acute MPTP regimen (20 mg/kg i.p. x 4 injections), it results in complete lethality,
consistent with other mouse strains (Schwarting et al. 1999). This is likely due to peripheral
toxicity, as female mice are particularly vulnerable to cardiovascular side effects in response to
MPTP (Jackson-Lewis and Przedborski 2007). However, death due to MPTP-induced
cardiovascular issues is unrelated to the loss of dopaminergic neurons in the nigrostriatal
pathway; thus, female mice treated with MPTP may succumb and die due to cardiovascular
events, before dopaminergic neuron loss in the SNpc may be observed. (Jackson-Lewis and
Przedborski 2007). We found that a dose of 12.5 mg/kg MPTP given 4 times i.p. allowed for
50% or greater survival in female Swiss-Webster mice, and interestingly, it did produce some
dopaminergic neuron loss within the SNpc.
Our data indicate that MPTP was capable of decreasing the number of dopaminergic
neurons within the SNpc of proestrus females. In addition, increased quinone formation is seen
in the striatum of proestrus female mice treated with MPTP. In contrast, anestrus females had no
significant differences in the number of dopaminergic neurons in the SNpc. Following this trend,
anestrus females showed no significant differences in quinone formation in the striatum. Taken
together, these results suggest that high physiological levels of estrogen in proestrus females may
actually sensitize female Swiss-Webster mice to MPTP. These data conflict with previous
studies that have shown that physiological levels of estrogen can be neuroprotective against
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neurotoxins such as MPTP, and proestrus females have less dopaminergic neuron loss when
compared to diestrus females (Dluzen and Horstink 2003; Dluzen et al. 1996; Gomez-Mancilla
and Bédard 1992; McArthur and Gillies 2011). While this may be true, these studies used
different animal models and dosing regimens. For example, Gomez-Mancilla and Bédard utilized
a female monkey model and administered MPTP immediately prior to administration of estrogen
(Gomez-Mancilla and Bédard 1992). In studies that utilized mouse models, different strains were
used, and the female mice were ovariectomized and then given a bolus of estrogen at the time of
the MPTP injection (Dluzen and Horstink 2003; Dluzen et al. 1996; McArthur and Gillies 2011).
However, it is also of note that levels of estrogen above physiological levels have been shown to
worsen the dopaminergic neuron loss within the SNpc in response to MPTP (Bourque et al.
2009; McArthur and Gillies 2011). In general, studies have shown that female mice exhibit more
variability in MPTP-induced neuronal damage to dopaminergic neurons when compared to
males (Przedborski et al. 2001). Given the effect of MPTP on dopaminergic neuron number in
the SNpc and quinone production in the striatum, it was surprising that GSH was not
significantly depleted in proestrus females exposed to chronic saline followed by MPTP.
However, females are known to have high concentrations of GSH, which may explain why
significant depletions in GSH were not seen (Gaignard et al. 2015).
Another unexpected finding was that chronic MPH did not seem to sensitize female mice
to SNpc dopaminergic cell loss in response to MPTP, as it does in males (Sadasivan et al. 2012).
Although there was a trend towards a decreased neuron number within the SNpc in the proestrus
groups exposed to MPH, there were no significant differences, unlike the mice treated with
chronic saline. Additionally, although there was a trend towards an increase in DA quinone
levels within the striatum, this was also not significantly changed in the chronic MPH mice.
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Again, this is in contrast to results observed in males, although notably, males are able to tolerate
and receive a higher dose of MPTP than could be utilized in females (Oakes et al. 2019).
Furthermore, MPTP induces a retrograde cell death, where synaptic terminals die prior to cell
bodies and may experience toxicity at lower doses of MPTP (Al Sweidi et al. 2012). Therefore,
the MPTP dose of 12.5 mg/kg may have been insufficient to result in cell body toxicity but was
sufficient in destroying the axon terminals. This could potentially lead to less DA release in the
striatum, and therefore, decreased quinone production in the striatum as well.
Of note, chronic MPH did appear to induce a significant depletion in striatal GSH in
proestrus females, and GSH was further reduced by MPTP. This suggests that the GSH available
was capable of handling the extra quinone production that was induced by chronic MPH and
MPTP. Of note, females are known to have increased concentration of GSH in mitochondria
when compared to males (Gaignard et al. 2015; Turrens 2003). Therefore, it is possible that the
increased concentrations of GSH were capable of dispatching any quinones that formed,
preventing excess quinones and loss of dopaminergic cell bodies within the SNpc.
In conclusion, female Swiss-Webster mice show dopaminergic neuron loss within the
SNpc at a MPTP dose of 12.5 mg/kg i.p. x 4 injections, when MPTP is administered in the
proestrus period. Additionally, an increase in levels of quinones within the striatum was also
observed when proestrus females were administered chronic saline followed by MPTP. Again,
this is surprising given the Swiss-Webster mouse is traditionally more resistant to MPTP and the
dose of MPTP utilized in females was less than that typically used in males. Taken together,
these results demonstrate that estrogen may sensitize dopaminergic neurons within the SNpc to
the Parkinsonian toxin, MPTP. Finally, although long-term MPH did not appear to increase
SNpc neuron loss or quinone formation, it did produce a significant depletion in GSH levels
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within the striatum, that was further reduced with MPTP. Thus, these data may provide insight
into possible consequences of long-term MPH exposure in a female model.

127

Acknowledgments
The authors would like to thank the ETSU Division of Laboratory Animal Research (DLAR)
staff, particularly, Dr. Greg Hanley, Jennie Hoard, and Robin King who provided guidance and
assistance with the mouse model. We would also like to acknowledge Angela Hanley for her
assistance with animal collections.

Funding Information
This work was supported by the American Foundation of Pharmaceutical Education and the
Gatton College of Pharmacy Department of Pharmaceutical Sciences.

Compliance with Ethical Standards
Ethical Approval
All protocols followed were approved by the University Committee on Animal Care (UCAC) at
East Tennessee State University. Experiments and procedures with the animals were performed
following the regulations set forth by the NIH Guide for the Care and Use of Laboratory
Animals.

Conflict of Interest
The authors declare that they have no conflicts of interest.

128

References
Al Sweidi S, Sánchez MG, Bourque M, Morissette M, Dluzen D, Di Paolo T (2012) Oestrogen
receptors and signalling pathways: implications for neuroprotective effects of sex steroids in
Parkinson's disease J Neuroendocrinol 24:48-61 doi:10.1111/j.1365-2826.2011.02193.x
Alam G, Miller DB, O'Callaghan JP, Lu L, Williams RW, Jones BC (2016) MPTP neurotoxicity
is highly concordant between the sexes among BXD recombinant inbred mouse strains
Neurotoxicology 55:40-47 doi:10.1016/j.neuro.2016.04.008
Bentley J, Snyder F, Brown SD, Brown RW, Pond BB (2015) Sex differences in the kinetic profiles
of d- and l- methylphenidate in the brains of adult rats Eur Rev Med Pharmacol Sci 19:2514-2519
Bourque M, Dluzen DE, Di Paolo T (2009) Neuroprotective actions of sex steroids in Parkinson's
disease Frontiers in neuroendocrinology 30:142-157 doi:10.1016/j.yfrne.2009.04.014
Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, Jiao Y, Smeyne RJ (2007) Response to 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a
divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra
pars compacta Brain research 1175:107-116 doi:10.1016/j.brainres.2007.07.067
Brown RW et al. (2012) Sex and dose-related differences in methylphenidate adolescent locomotor
sensitization and effects on brain-derived neurotrophic factor Journal of psychopharmacology
(Oxford, England) 26:1480-1488 doi:10.1177/0269881112454227
Cummins ED, Griffin SB, Duty CM, Peterson DJ, Burgess KC, Brown RW (2014) The role of
dopamine D₁ and D₂ receptors in adolescent methylphenidate conditioned place preference: sex
differences and brain-derived neurotrophic factor Dev Neurosci
36:277-286
doi:10.1159/000360636
Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR (2015)
Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based
assessment Drug and alcohol dependence 146:30-38 doi:10.1016/j.drugalcdep.2014.10.027
Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ (2018)
Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children
and
Adolescents,
2016
J
Clin
Child
Adolesc
Psychol
47:199-212
doi:10.1080/15374416.2017.1417860
Disshon KA, Dluzen DE (2000) Estrogen reduces acute striatal dopamine responses in vivo to the
neurotoxin MPP+ in female, but not male rats Brain research 868:95-104 doi:10.1016/s00068993(00)02329-5
Dluzen D, Horstink M (2003) Estrogen as neuroprotectant of nigrostriatal dopaminergic system:
laboratory and clinical studies Endocrine 21:67-75 doi:10.1385/endo:21:1:67

129

Dluzen DE, McDermott JL, Liu B (1996) Estrogen alters MPTP-induced neurotoxicity in female
mice: effects on striatal dopamine concentrations and release Journal of neurochemistry 66:658666
Frolich J, Banaschewski T, Dopfner M, Gortz-Dorten A (2014) An evaluation of the
pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder
Expert Opin Drug Metab Toxicol 10:1169-1183 doi:10.1517/17425255.2014.922542
Gaignard P et al. (2015) Effect of Sex Differences on Brain Mitochondrial Function and Its
Suppression by Ovariectomy and in Aged Mice Endocrinology 156:2893-2904
doi:10.1210/en.2014-1913
Gangrade BK, Dominic CJ (1984) Studies of the male-originating pheromones involved in the
Whitten effect and Bruce effect in mice Biol Reprod 31:89-96 doi:10.1095/biolreprod31.1.89
Gerasimov MR et al. (2000) Comparison between intraperitoneal and oral methylphenidate
administration: A microdialysis and locomotor activity study The Journal of pharmacology and
experimental therapeutics 295:51-57
Golan D TA, Armstrong EJ (2011) Principles of Pharmacology: The Pathophysiologic Basis of
Drug Therapy. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 3 edn.
LWW,
Gomez-Mancilla B, Bédard PJ (1992) Effect of estrogen and progesterone on L-dopa induced
dyskinesia in MPTP-treated monkeys Neuroscience letters 135:129-132 doi:10.1016/03043940(92)90152-w
Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ (1999) Differential strain susceptibility
following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an
autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus Brain research
828:91-103
Heikkila RE (1985) Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) in Swiss-Webster mice from different sources European journal of pharmacology
117:131-133 doi:10.1016/0014-2999(85)90482-0
Hoskins JA, Davis LJ (1989) The acute effect on levels of catecholamines and metabolites in brain,
of a single dose of MPTP in 8 strains of mice Neuropharmacology 28:1389-1397
doi:10.1016/0028-3908(89)90015-4
Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's
disease Nature protocols 2:141-151 doi:10.1038/nprot.2006.342
Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG (2019) Dopamine:
Functions, Signaling, and Association with Neurological Diseases Cellular and molecular
neurobiology 39:31-59 doi:10.1007/s10571-018-0632-3
Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010) Effects of acute and chronic
administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline,
130

dopamine and serotonin in the prefrontal cortex and striatum of mice Journal of neurochemistry
114:259-270 doi:10.1111/j.1471-4159.2010.06750.x
Ma W, Miao Z, Novotny MV (1998) Role of the adrenal gland and adrenal-mediated chemosignals
in suppression of estrus in the house mouse: the lee-boot effect revisited Biol Reprod 59:13171320 doi:10.1095/biolreprod59.6.1317
Martins MR, Reinke A, Petronilho FC, Gomes KM, Dal-Pizzol F, Quevedo J (2006)
Methylphenidate treatment induces oxidative stress in young rat brain Brain research 1078:189197 doi:10.1016/j.brainres.2006.01.004
Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA (2004) Weekend
holidays during methylphenidate use in ADHD children: a randomized clinical trial J Child
Adolesc Psychopharmacol 14:195-206 doi:10.1089/1044546041649066
Mazzulli JR, Burbulla LF, Krainc D, Ischiropoulos H (2016) Detection of Free and Protein-Bound
ortho-Quinones by Near-Infrared Fluorescence Analytical chemistry 88:2399-2405
doi:10.1021/acs.analchem.5b04420
McArthur S, Gillies GE (2011) Peripheral vs. Central Sex Steroid Hormones in Experimental
Parkinson's Disease Frontiers in endocrinology 2:82 doi:10.3389/fendo.2011.00082
McLean AC, Valenzuela N, Fai S, Bennett SA (2012) Performing vaginal lavage, crystal violet
staining, and vaginal cytological evaluation for mouse estrous cycle staging identification Journal
of visualized experiments : JoVE:e4389 doi:10.3791/4389
Monzani E et al. (2018) Dopamine, oxidative stress and protein-quinone modifications in
Parkinson's and other neurodegenerative diseases Angewandte Chemie (International ed in
English) doi:10.1002/anie.201811122
Moratalla R et al. (2017) Amphetamine-related drugs neurotoxicity in humans and in experimental
animals:
Main
mechanisms
Progress
in
neurobiology
155:149-170
doi:10.1016/j.pneurobio.2015.09.011
Motaghinejad M, Motevalian M, Shabab B (2016) Effects of chronic treatment with
methylphenidate on oxidative stress and inflammation in hippocampus of adult rats Neuroscience
letters 619:106-113 doi:10.1016/j.neulet.2015.12.015
Oakes HV, Ketchem S, Hall AN, Ensley T, Archibald KM, Pond BB (2019) Chronic
methylphenidate induces increased quinone production and subsequent depletion of the
antioxidant
glutathione
in
the
striatum
Pharmacol
Rep
71:1289-1292
doi:10.1016/j.pharep.2019.08.003
Park ES et al. (2007) Glutathione prevented dopamine-induced apoptosis of melanocytes and its
signaling Journal of dermatological science 47:141-149 doi:10.1016/j.jdermsci.2007.03.009
Perfeito R, Cunha-Oliveira T, Rego AC (2013) Reprint of: revisiting oxidative stress and
mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of
131

amphetamine drugs of abuse Free
doi:10.1016/j.freeradbiomed.2013.05.042

radical

biology

&

medicine

62:186-201

Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M (2001)
The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review
of its utility and safety Journal of neurochemistry 76:1265-1274 doi:10.1046/j.14714159.2001.00183.x
Roche AF, Lipman RS, Overall JE, Hung W (1979) The effects of stimulant medication on the
growth of hyperkinetic children Pediatrics 63:847-850
Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ (2012) Methylphenidate exposure
induces dopamine neuron loss and activation of microglia in the basal ganglia of mice PloS one
7:e33693 doi:10.1371/journal.pone.0033693
Schwarting RK, Sedelis M, Hofele K, Auburger GW, Huston JP (1999) Strain-dependent recovery
of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's
disease Neurotox Res 1:41-56 doi:10.1007/bf03033338
Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP
susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and
strain differences Behavior genetics 30:171-182
Sonsalla PK, Heikkila RE (1988) Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) and methamphetamine in several strains of mice Progress in neuropsychopharmacology & biological psychiatry 12:345-354 doi:10.1016/0278-5846(88)90054-1
Stahl S (2008) Stahl's Essential Psychopharmacology: Neuroscientific Basis & Practical
Applications. . Cambridge Medicine, 3 edn. Cambridge University Press,
Stokes AH, Lewis DY, Lash LH, Jerome WG, 3rd, Grant KW, Aschner M, Vrana KE (2000)
Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis
Brain research 858:1-8
Sundström E, Strömberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in
C57BL/6 mice. Comparison with three other strains of mice Brain research 405:26-38
doi:10.1016/0006-8993(87)90986-3
Turrens JF (2003) Mitochondrial formation of reactive oxygen species The Journal of physiology
552:335-344 doi:10.1113/jphysiol.2003.049478
Valvassori SS et al. (2007) Sensitization and cross-sensitization after chronic treatment with
methylphenidate
in
adolescent
Wistar
rats
Behav
Pharmacol
18:205-212
doi:10.1097/FBP.0b013e328153daf5
Vidyadhara DJ, Yarreiphang H, Raju TR, Alladi PA (2017) Admixing of MPTP-Resistant and
Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced
Neurodegeneration Mol Neurobiol 54:6148-6162 doi:10.1007/s12035-016-0158-y
132

Walker QD, Ray R, Kuhn CM (2006) Sex differences in neurochemical effects of dopaminergic
drugs in rat striatum Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology 31:1193-1202 doi:10.1038/sj.npp.1300915
Whitten MK (1957) Effect of exteroceptive factors on the oestrous cycle of mice Nature 180:1436
doi:10.1038/1801436a0
Zhou ZD, Lim TM (2009) Roles of glutathione (GSH) in dopamine (DA) oxidation studied by
improved tandem HPLC plus ESI-MS Neurochemical research 34:316-326 doi:10.1007/s11064008-9778-6

133

CHAPTER 5. SUMMARY

The number of individuals diagnosed with ADHD has steadily increased since the early
1990s (Danielson et al. 2018). Psychostimulants have remained first-line treatment, and the most
commonly prescribed drug to treat ADHD is MPH (Gibson et al. 2006; Hanwella et al. 2011).
Initially, ADHD was thought to be a childhood disorder and that medication was not needed
once adulthood was reached; however, ADHD is now thought to be a life-long disorder. As such,
individuals are taking MPH for many years. Unfortunately, a vast majority of the scientific
literature focuses on the short-term consequences of MPH exposure. Furthermore, reports of
abuse and misuse of MPH have increased. For example, in 2017, an estimated 12% of college
students reported using ADHD as a “cognitive enhancer” (Abelman 2017). Additionally, other
studies have found that individuals inject MPH to experience euphoria (Frauger et al. 2016).
Finally, most studies investigating MPH have utilized only males; this is unfortunate as the few
studies that have included females show that they respond differently to MPH. As such this
dissertation endeavored to fill the gap in understanding long-term MPH exposure, the effects of
both therapeutic and abusive doses, and the differential effects of the drug in males and females.
MPH acts by increasing the amounts of DA and NE in the synaptic cleft, and thus,
chronic MPH may have long-term consequences on dopaminergic pathways within the brain.
This study focused on MPH modulation of the mesolimbic and nigrostriatal pathways. The
mesolimbic pathway is well-known for its role in reward, as neurons project from the ventral
tegmental area to the nucleus accumbens. However, mesolimbic dopamine neurons also project
to the hippocampus, an area of the brain that plays an important role in memory and recall.
Dopaminergic neurons within the nigrostriatal pathway are important in motor function, and a
loss of DA neurons in this pathway leads to the movement disorder, Parkinson’s disease.
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In chapter 2, we evaluated the effects of chronic exposure to low or high doses of MPH
on neurogenesis in the hippocampus of the mesolimbic pathway. Additionally, these studies
included an investigation of how proteins involved in neurogenesis are altered due to chronic
MPH exposure. We proposed that treatment with chronic low or high doses of MPH may affect
the proliferation and survival of granule cells within the dentate gyrus of the hippocampus and
that MPH may influence hippocampal neurogenesis by altering the expression of proteins that
influence neurogenesis, including BDNF, GDNF, VEGF, TrkB, and beta-catenin. In this study,
mice received chronic low (1 mg/kg) or high (10 mg/kg) i.p. doses of MPH for 28 or 56 days.
Interestingly, MPH, at both doses, increased neurogenesis. However, if MPH treatment was not
continued, the newly generated cells did not survive after 28 days. If treatment was continued,
the newly generated neurons survived only in the mice receiving low dose MPH. To investigate
the mechanism for this effect, we examined levels of proteins linked to cell proliferation in the
hippocampus. BDNF or GDNF levels were not significantly different between groups. However,
hippocampal VEGF, TrkB, and beta-catenin were significantly increased in mice receiving low
dose MPH for 28 days compared to controls. Interestingly, high dose MPH significantly
decreased beta-catenin after 28 days and decreased VEGF, beta-catenin, and TrkB after 56 days
compared to controls. Thus, low dose MPH appears to increase cell proliferation and cell
survival in the hippocampus, and these effects may be mediated by increases in VEGF, TrkB,
and beta-catenin. While high dose MPH may initially increase neuronal proliferation, newlygenerated neurons are unable to survive long-term, possibly due to decreases in VEGF, TrkB and
beta-catenin.
In chapter 3, we examined if chronic exposure to MPH will render dopaminergic neurons
within the nigrostriatal pathway more sensitive to oxidative stress. We utilized the Parkinsonian
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toxin, MPTP, in this model as it is known to produce oxidative stress and neurodegeneration of
neurons within the substantia nigra. A previous study by my advisor, Brooks Pond, showed that
chronic MPH rendered dopaminergic neurons in the nigrostriatal pathway to be more sensitive to
MPTP (Sadasivan et al. 2012). We hypothesized that chronic MPH exposure leads to oxidative
stress caused by the autoxidation of excess DA to a DA-o-quinone and that it is this oxidative
stress that renders dopaminergic neurons within the striatum to be more sensitive to MPTP.
Normally, the antioxidant GSH conjugates to the quinone, protecting neurons from oxidative
stress; however, we proposed that MPH induced excess DA quinone production may lead to
GSH depletion. To investigate this, male mice received chronic low or high doses of MPH and
were exposed to saline or MPTP following a 1-week washout. Quinone formation in the striatum
was examined via dot blot, and striatal GSH was quantified using a GSH assay. Our results
showed that quinone formation increased with increasing doses of MPH. Additionally, MPH
dose-dependently resulted in a depletion of GSH, which was further depleted following MPTP
treatment. Thus, the increased sensitivity of DA neurons to MPTP toxicity following chronic
methylphenidate exposure may be due to quinone production and subsequent depletion of GSH.
In chapter 4, we examined the interaction between chronic MPH and vulnerability to
MPTP in a female model. Previously, studies have found that estrogen is neuroprotective against
MPTP (Dluzen and Horstink 2003; Dluzen et al. 1996; Gomez-Mancilla and Bédard 1992;
McArthur and Gillies 2011). Therefore, we proposed that estrogen may play a protective role
when dopaminergic neurons within the nigrostriatal pathway are chronically exposed to MPH.
Female mice received that same treatment as the male mice in chapter 3; however, the mice were
either in anestrus (low estrogen) or proestrus (high estrogen) at the time of the MPTP injection.
Interestingly, proestrus females exhibited greater sensitivity to MPTP, with significantly reduced
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dopaminergic neurons in the SN and significant increases in DA quinone production. Chronic
MPH exposure contributed to GSH depletion, but surprisingly, it did not increase DA quinone
levels or dopaminergic cell loss. There were no significant differences in anestrus animals, with
the exception of a depletion in GSH seen when animals received chronic high dose MPH
followed by MPTP. Thus, estrogen may actually sensitize neurons to MPTP in this model, and
chronic MPH may contribute to GSH depletion within the striatum. This study provides insight
into how chronic psychostimulant use may affect males and females differently.
As more individuals are prescribed MPH and as the length of MPH treatment increases,
the more important it becomes to study the chronic effects of this drug on important
dopaminergic pathways. Altogether, this work has contributed to understanding how chronic
MPH exposure may alter the mesolimbic and nigrostriatal dopaminergic pathways. Interestingly,
MPH may increase neurogenesis within the hippocampus through mesolimbic modulation.
However, this work supports epidemiological studies that indicate psychostimulant use may
contribute to degenerative changes within the nigrostriatal pathway. Finally, this study highlights
the need to include both males and females in MPH studies. Hopefully, the knowledge of how
chronic MPH affects dopaminergic plasticity can be utilized when physicians and patients are
making decisions about how best to utilize this drug.
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